Please type a plus sign (+) inside this box +

Attorney Docket P1093P1D1 **PATENT**

CERTIFICATION UNDER 37 CFR 1.10

Express Mail Number

November 27, 2000: Date of Deposit

Et 599584388US: Express Mail Number.

November 27, 2000: Date of Deposit.

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein. are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Manuel Baca, Foster City, CA James A. Wells, Burlingame, CA Leonard G. Presta, San Francisco, CA Henry B. Lowman, El Granada, CA Yvonne Man-yee Chen, San Mateo, CA

Title: ANTI-VEGF ANTIBODIES

1. Type of Application

- [] This application is for an original, non-provisional application.
- This is a non-provisional application claiming priority to provisional application no. __ , filed [] ____, the entire disclosure of which is hereby incorporated by reference.
- [] continuation [] continuation-in-part application [X] [X] divisional This is a claiming priority to application Serial Number 08/908,469, filed August 6, 1997, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

- 80 pages of specification
- pages of claims
- page(s) of abstract
- sheet(s) of drawings 16
 - [X] informal ∏ formal

3.

4.

5.

	ration or Oath
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An executed declaration of the inventor(s) [] is enclosed [] will follow.
X	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
Assig	nment
	(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.
X	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
Ame	ndments (for continuation and divisional applications)
X	Cancel in this application original claims <u>1-38</u> of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
Rela	properly numbered consecutively beginning with the number next following the highest
Rela	properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119
X	properly numbered consecutively beginning with the number next following the highes numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119 Amend the specification by inserting before the first line the sentence:
	properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119 Amend the specification by inserting before the first line the sentence:
X Thi	properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119 Amend the specification by inserting before the first line the sentence: is is a non-provisional application continuation divisional

herein by reference and to which application(s) priority is claimed under 35 USC §120. -- International Application _ filed on _ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC

§120.--

6.

7.

	provisional application Nofiled _, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.—.
6.	Payment of Fees
	Applicants request deferral of payment of the filing fee until submission of the missing parts of application. DO NOT CHARGE THE FILING FEE AT THIS TIME.
7.	Additional Papers Enclosed Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence. [X] Associate Power of Attorney. Other:
8. applica	Maintenance of Copendency of Prior Application (for continuation and divisional ations) [This item must be completed and the necessary papers filed in the prior application if the period sein the prior application has run]
	A petition, fee and/or response has been filed to extend the term in the pending prior application until A copy of the petition for extension of time in the <i>prior</i> application is attached.
9.	Correspondence Address:
<u>X</u>	Address all future communications to:
	Attas Stayon V Cui

Attn: Steven X. Cui GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080-4990 (650) 225-8674

> Respectfully submitted, GENENTECH, INC.

Date: November 27, 2000

Steven X. Cui Reg. No. 44,637

Telephone No. (650) 225-8674

09157

PATENT TRADEMARK OFFICE

Harry Street

20

₫, ♣

Ella Ami

25

30

ANTI-VEGF ANTIBODIES

CROSS REFERENCES

This application is a continuation-in-part of co-pending U.S. Application Serial No. 08/833,504, filed April 7, 1997, which application is incorporated herein by reference and to which application priority is claimed under 35 USC §120.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates generally to anti-VEGF antibodies and, in particular, to humanized anti-VEGF antibodies and variant anti-VEGF antibodies.

Description of Related Art

It is now well established that angiogenesis is implicated in the pathogenesis of a variety of disorders. These include solid tumors, intraocular neovascular syndromes such as proliferative retinopathies or age-related macular degeneration (AMD), rheumatoid arthritis, and psoriasis (Folkman et al. J. Biol. Chem. 267:10931-10934 (1992); Klagsbrun et al. Annu. Rev. Physiol. 53:217-239 (1991); and Garner A, Vascular diseases. In: Pathobiology of ocular disease. A dynamic approach. Garner A, Klintworth GK, Eds. 2nd Edition Marcel Dekker, NY, pp 1625-1710 (1994)). In the case of solid tumors, the neovascularization allows the tumor cells to acquire a growth advantage and proliferative autonomy compared to the normal cells. Accordingly, a correlation has been observed between density of microvessels in tumor sections and patient survival in breast cancer as well as in several other tumors (Weidner et al. N Engl J Med 324:1-6 (1991); Horak et al. Lancet 340:1120-1124 (1992); and Macchiarini et al. Lancet 340:145-146 (1992)).

The search for positive regulators of angiogenesis has yielded many candidates, including aFGF, bFGF, TGF-α, TGF-β, HGF, TNF-α, angiogenin, IL-8, etc. (Folkman *et al.* and Klagsbrun

et al). The negative regulators so far identified include thrombospondin (Good et al. Proc. Natl. Acad. Sci. USA. 87:6624-6628 (1990)), the 16-kilodalton N-terminal fragment of prolactin (Clapp et al. Endocrinology, 133:1292-1299 (1993)), angiostatin (O'Reilly et al. Cell, 79:315-328 (1994)) and endostatin (O'Reilly et al. Cell, 88:277-285 (1996)).

5

10

Harm the state of the state of

į. į.

fi de

25

30

Work done over the last several years has established the key role of vascular endothelial growth factor (VEGF) in the regulation of normal and abnormal angiogenesis (Ferrara et al. Endocr. Rev. 18:4-25 (1997)). The finding that the loss of even a single VEGF allele results in embryonic lethality points to an irreplaceable role played by this factor in the development and differentiation of the vascular system (Ferrara et al.). Furthermore, VEGF has been shown to be a key mediator of neovascularization associated with tumors and intraocular disorders (Ferrara et al.). The VEGF mRNA is overexpressed by the majority of human tumors examined (Berkman et al. J Clin Invest 91:153-159 (1993); Brown et al. Human Pathol.. 26:86-91 (1995); Brown et al. Cancer Res. 53:4727-4735 (1993); Mattern et al. Brit. J. Cancer. 73:931-934 (1996); and Dvorak et al. Am J. Pathol. 146:1029-1039 (1995)). Also, the concentration of VEGF in eye fluids are highly correlated to the presence of active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies (Aiello et al. N. Engl. J. Med. 331:1480-1487 (1994)). Furthermore, recent studies have demonstrated the localization of VEGF in choroidal neovascular membranes in patients affected by AMD (Lopez et al. Invest. Ophtalmo. Vis. Sci. 37:855-868 (1996)). Anti-VEGF neutralizing antibodies suppress the growth of a variety of human tumor cell lines in nude mice (Kim et al. Nature 362:841-844 (1993); Warren et al. J. Clin. Invest. 95:1789-1797 (1995); Borgström et al. Cancer Res. 56:4032-4039 (1996); and Melnyk et al. Cancer Res. 56:921-924 (1996)) and also inhibit intraocular angiogenesis in models of ischemic retinal disorders (Adamis et al. Arch. Ophthalmol. 114:66-71 (1996)). Therefore, anti-VEGF monoclonal antibodies or other inhibitors of VEGF action are promising candidates for the treatment of solid tumors and various intraocular neovascular disorders.

SUMMARY OF THE INVENTION

This application describes humanized anti-VEGF antibodies and anti-VEGF antibody variants with desirable properties from a therapeutic perspective, including strong binding affinity for VEGF; the ability to inhibit VEGF-induced proliferation of endothelial cells *in vitro*; and the ability

to inhibit VEGF-induced angiogenesis in vivo.

5

10

į.

1.4

25

30

145

The preferred humanized anti-VEGF antibody or variant anti-VEGF antibody herein binds human VEGF with a K_d value of no more than about 1 x 10°M and preferably no more than about 5 x 10°M. In addition, the humanized or variant anti-VEGF antibody may have an ED50 value of no more than about 5nM for inhibiting VEGF-induced proliferation of endothelial cells *in vitro*. The humanized or variant anti-VEGF antibodies of particular interest herein are those which inhibit at least about 50% of tumor growth in an A673 *in vivo* tumor model, at an antibody dose of 5mg/kg.

In one embodiment, the anti-VEGF antibody has a heavy and light chain variable domain, wherein the heavy chain variable domain comprises hypervariable regions with the following amino acid sequences: CDRH1 (GYX₁FTX₂YGMN, wherein X₁ is T or D and X₂ is N or H; SEQ ID NO:128), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPX₁YYGX₂SHWYFDV, wherein X₁ is Y or H and X₂ is S or T; SEQ ID NO:129). For example, the heavy chain variable domain may comprise the amino acid sequences of CDRH1 (GYTFTNYGMN; SEQ ID NO:1), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPHYYGSSHWYFDV; SEQ ID NO:3). Preferably, the three heavy chain hypervariable regions are provided in a human framework region, *e.g.*, as a contiguous sequence represented by the following formula: FR1-CDRH1-FR2-CDRH2-FR3-CDRH3-FR4.

The invention further provides an anti-VEGF antibody heavy chain variable domain comprising the amino acid sequence:

EVQLVESGGGLVQPGGSLRLSCAASGYX₁FTX₂YGMNWVRQAPGKGLEWVGWINTYTGEPT YAADFKRRFTFSLDTSK STAYLQMNSLRAEDTAVYYCAKYPX₃YYGX₄SHWYFDVWGQGTLV TVSS (SEQ ID NO:125), wherein X₁ is T or D; X₂ is N or H; X₃ is Y or H and X₄ is S or T. One particularly useful heavy chain variable domain sequence is that of the F(ab)-12 humanized antibody of Example 1 and comprises the heavy chain variable domain sequence of SEQ ID NO:7. Such preferred heavy chain variable domain sequences may be combined with the following preferred light chain variable domain sequences or with other light chain variable domain sequences, provided that the antibody so produced binds human VEGF.

The invention also provides preferred light chain variable domain sequences which may be combined with the above-identified heavy chain variable domain sequences or with other heavy

30

5

10

chain variable domain sequences, provided that the antibody so produced retains the ability to bind to human VEGF. For example, the light chain variable domain may comprise hypervariable regions with the following amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS; SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6). Preferably, the three light chain hypervariable regions are provided in a human framework region, *e.g.*, as a contiguous sequence represented by the following formula: FR1-CDRL1-FR2-CDRL2-FR3-CDRL3-FR4.

In one embodiment, the invention provides a humanized anti-VEGF antibody light chain variable domain comprising the amino acid sequence:

DIQX₁TQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR (SEQ ID NO:124), wherein X₁ is M or L. One particularly useful light chain variable domain sequence is that of the F(ab)-12 humanized antibody of Example 1 and comprises the light chain variable domain sequence of SEQ ID NO:8.

The invention also provides a variant of a parent anti-VEGF antibody (which parent antibody is preferably a humanized or human anti-VEGF antibody), wherein the variant binds human VEGF and comprises an amino acid substitution in a hypervariable region of the heavy or light chain variable domain of the parent anti-VEGF antibody. The variant preferably has one or more substitution(s) in one or more hypervariable region(s) of the anti-VEGF antibody. Preferably, the substitution(s) are in the heavy chain variable domain of the parent antibody. For example, the amino acid subsition(s) may be in the CDRH1 and/or CDRH3 of the heavy chain variable domain. Preferably, there are substitutions in both these hypervariable regions. Such "affinity matured" variants are demonstrated herein to bind human VEGF more strongly than the parent anti-VEGF antibody from which they are generated, i.e., they have a K₄ value which is significantly less than that of the parent anti-VEGF antibody. Preferably, the variant has an ED50 value for inhibiting VEGF-induced proliferation of endothelial cells in vitro which is at least about 10 fold lower, preferably at least about 20 fold lower, and most preferably at least about 50 fold lower, than that of the parent anti-VEGF antibody. One particularly prefered variant is the Y0317 variant of Example 3, which has a CDRH1 comprising the amino acid sequence: GYDFTHYGMN (SEQ ID NO:126) and a CDRH3 comprising the amino acid sequence:YPYYYGTSHWYFDV (SEQ ID

30

5

NO:127). These hypervariable regions and CDRH2 are generally provided in a human framework region, e.g., resulting in a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:116. Such heavy chain variable domain sequences are optionally combined with a light chain variable domain comprising the amino acid sequence of SEQ ID NO:124, and preferably the light chain variable domain amino acid sequence of SEQ ID NO:115.

Various forms of the antibody are contemplated herein. For example, the anti-VEGF antibody may be a full length antibody (e.g. having an intact human Fc region) or an antibody fragment (e.g. a Fab, Fab' or F(ab')₂). Furthermore, the antibody may be labeled with a detectable label, immobilized on a solid phase and/or conjugated with a heterologous compound (such as a cytotoxic agent).

Diagnostic and therapeutic uses for the antibody are contemplated. In one diagnostic application, the invention provides a method for determining the presence of VEGF protein comprising exposing a sample suspected of containing the VEGF protein to the anti-VEGF antibody and determining binding of the antibody to the sample. For this use, the invention provides a kit comprising the antibody and instructions for using the antibody to detect the VEGF protein.

The invention further provides: isolated nucleic acid encoding the antibody; a vector comprising that nucleic acid, optionally operably linked to control sequences recognized by a host cell transformed with the vector; a host cell comprising that vector; a process for producing the antibody comprising culturing the host cell so that the nucleic acid is expressed and, optionally, recovering the antibody from the host cell culture (e.g. from the host cell culture medium). The invention also provides a composition comprising the anti-VEGF antibody and a pharmaceutically acceptable carrier or diluent. The composition for therapeutic use is sterile and may be lyophilized. The invention further provides a method for treating a mammal suffering from a tumor or retinal disorder, comprising administering a therapeutically effective amount of the anti-VEGF antibody to the mammal.

Brief Description of the Drawings

Figs. 1A and 1B depict the amino acid sequences of variable heavy domain (SEQ ID NO:9) and light domain (SEQ ID NO:10) of muMAbVEGF A.4.6.1, variable heavy domain (SEQ ID NO:7)

and light domain (SEQ ID NO:8) of humanized F(ab) (F(ab)-12) and human consensus frameworks (hum III for heavy subgroup III (SEQ ID NO:11); humκ1 for light κ subgroup I (SEQ ID NO:12)). Fig. 1A aligns variable heavy domain sequences and Fig. 1B aligns variable light domain sequences. Asterisks indicate differences between humanized F(ab)-12 and the murine MAb or between F(ab)-12 and the human framework. Complementarity Determining Regions (CDRs) are underlined.

5

10

With the

25

30

Fig. 2 is a ribbon diagram of the model of humanized F(ab)-12 VL and VH domains. VL domain is shown in brown with CDRs in tan. The sidechain of residue L46 is shown in yellow. VH domain is shown in purple with CDRs in pink. Sidechains of VH residues changed from human to murine are shown in yellow.

Fig. 3 depicts inhibition of VEGF-induced mitogenesis by humanized anti-VEGF F(ab)-12 from Example 1. Bovine adrenal cortex-derived capillary endothelial cells were seeded at the density of 6 X 10³ cells/well in six well plates, as described in Example 1. Either muMAb VEGF A.4.6.1 or rhuMAb VEGF (IgG1; F(ab)-12) was added at the indicated concentrations. After 2-3 hours, rhVEGF165 was added at the final concentration of 3 ng/ml. After five or six days, cells were trypsinized and counted. Values shown are means of duplicate determinations. The variation from the mean did not exceed 10%.

Fig. 4 shows inhibition of tumor growth *in vivo* by humanized anti-VEGF F(ab)-12 from Example 1. A673 rhabdomyosarcoma cells were injected in BALB/c nude mice at the density of 2×10^6 per mouse. Starting 24 hours after tumor cell inoculation, animals were injected with a control MAb, muMAb VEGF A4.6.1 or rhuVEGF MAb (IgG1; F(ab)-12) twice weekly, intra peritoneally. The dose of the control Mab was 5 mg/kg; the anti-VEGF MAbs were given at 0.5 or 5 mg/kg, as indicated (n = 10). Four weeks after tumor cell injection, animals were euthanized and tumors were removed and weighed. *: significant difference when compared to the control group by ANOVA (p < 0.05).

Figs. 5A and 5B show the acid sequences of the light and heavy variable domains respectively of murine antibody A4.6.1 (SEQ ID NO:10 for the VL and SEQ ID NO:9 for the VH) and humanized A4.6.1 variants hu2.0 (SEQ ID NO:13 for the VL and SEQ ID NO:14 for the VH) and hu2.10 (SEQ ID NO:15 for the VL and SEQ ID NO:16 for the VH) from Example 2. Sequence numbering is according to Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.

Public Health Service, National Institutes of Health, Bethesda, MD. (1991) and mismatches are indicated by asterisks (murine A4.6.1 vs hu2.0) or bullets (hu2.0 vs hu2.10). Variant hu2.0 contains only the CDR sequences (bold) from the murine antibody grafted onto a human light chain κ subgroup I consensus framework (SEQ ID NO:12) and heavy chain subgroup III consensus framework (SEQ ID NO:11). hu2.10 was the consensus humanized clone obtained from phage sorting experiments described herein.

Fig. 6 depicts framework residues targeted for randomization in Example 2.

5

10

The first was the state of the first of the

25

30

Fig. 7 depicts the phagemid construct for surface display of Fab-pIII fusions on phage. The phagemid encodes a humanized version of the Fab fragment for antibody A4.6.1 fused to a portion of the M13 gene III coat protein. The fusion protein consists of the Fab joined at the carboxyl terminus of the heavy chain to a single glutamine residue (from suppression of an amber codon in *supE E. coli*), then the C-terminal region of the gene III protein (residues 249-406). Transformation into F⁺E. *coli*, followed by superinfection with M13KO7 helper phage, produces phagemid particles in which a small proportion of these display a single copy of the fusion protein.

Figs. 8A-E depict the double stranded nucleotide sequence (SEQ ID NO:99) for phage-display antibody vector phMB4-19-1.6 in Example 3 and the amino acid sequence encoded thereby (SEQ ID NO:100).

Figs. 9A and 9B depict an alignment of the amino acid sequences for the light and heavy variable domains respectively of affinity matured anti-VEGF variants in Example 3, compared to F(ab)-12 of Example 1 (SEQ ID NO's 8 and 7 for light and heavy variable domains, respectively). CDRs are underlined and designated by L, light, or H, heavy chain, and numbers 1-3. Residues are numbered sequentially in the VL and VH domains, as opposed to the Kabat numbering scheme. The template molecule, MB1.6 (SEQ ID NO's 101 and 102 for light and heavy variable domains, respectively) is shown, along with variants: H2305.6 (SEQ ID NO's 103 and 104 for light and heavy variable domains, respectively), Y0101 (SEQ ID NO's 105 and 106 for light and heavy variable domains, respectively), and Y0192 (SEQ ID NO's 107 and 108 for light and heavy variable domains, respectively). Differences from F(ab)-12 are shown in shaded boxes.

Figs. 10A and 10B depict an alignment of the amino acid sequences for the light and heavy variable domains respectively of affinity matured anti-VEGF variants from Example 3 compared to F(ab)-12 of Example 1 (SEQ ID NO's 8 and 7 for light and heavy variable domains,

30

5

10

respectively). CDRs are underlined and designated by L, light, or H, heavy chain, and numbers 1-3. The variants are designated Y0243-1 (SEQ ID NO's 109 and 110 for light and heavy variable domains, respectively), Y0238-3 (SEQ ID NO's 111 and 112 for light and heavy variable domains, respectively), Y0313-1 (SEQ ID NO's 113 and 114 for light and heavy variable domains, respectively), and Y0317 (SEQ ID NO's 115 and 116 for light and heavy variable domains, respectively). Differences from F(ab)-12 are shown in shaded boxes.

Fig. 11 depicts the results of the HuVEC activity assay in Example 3 for variants Y0238-3, Y0192 and Y0313-1 as well as full length F(ab)-12 from Example 1.

Fig. 12 depicts inhibition of VEGF-induced mitogenesis by full length F(ab)-12 from Example 1 (rhuMAb VEGF), a Fab fragment of F(ab)-12 from Example 1 (rhuFab VEGF), and a Fab fragment of affinity matured variant Y0317 from Example 3 (rhuFab VEGF (affinity matured)).

Detailed Description of the Preferred Embodiments

I. Definitions

The term "human VEGF" as used herein refers to the 165-amino acid human vascular endothelial cell growth factor, and related 121-, 189-, and 206-amino acid vascular endothelial cell growth factors, as described by Leung *et al.*, *Science* 246:1306 (1989), and Houck *et al.*, *Mol. Endocrin.* 5:1806 (1991) together with the naturally occurring allelic and processed forms of those growth factors.

The present invention provides anti-VEGF antagonistic antibodies which are capable of inhibiting one or more of the biological activities of VEGF, for example, its mitogenic or angiogenic activity. Antagonists of VEGF act by interfering with the binding of VEGF to a cellular receptor, by incapacitating or killing cells which have been activated by VEGF, or by interfering with vascular endothelial cell activation after VEGF binding to a cellular receptor. All such points of intervention by a VEGF antagonist shall be considered equivalent for purposes of this invention.

The term "VEGF receptor" or "VEGFr" as used herein refers to a cellular receptor for VEGF, ordinarily a cell-surface receptor found on vascular endothelial cells, as well as variants thereof which retain the ability to bind hVEGF. One example of a VEGF receptor is the *fms*-like tyrosine kinase (*flt*), a transmembrane receptor in the tyrosine kinase family. DeVries *et al.*, *Science* 255:989 (1992); Shibuya *et al.*, *Oncogene* 5:519 (1990). The *flt* receptor comprises an

30

5

10

extracellular domain, a transmembrane domain, and an intracellular domain with tyrosine kinase activity. The extracellular domain is involved in the binding of VEGF, whereas the intracellular domain is involved in signal transduction. Another example of a VEGF receptor is the *flk-1* receptor (also referred to as KDR). Matthews *et al.*, *Proc. Nat. Acad. Sci.* 88:9026 (1991); Terman *et al.*, *Oncogene* 6:1677 (1991); Terman *et al.*, *Biochem. Biophys. Res. Commun.* 187:1579 (1992). Binding of VEGF to the *flt* receptor results in the formation of at least two high molecular weight complexes, having apparent molecular weight of 205,000 and 300,000 Daltons. The 300,000 Dalton complex is believed to be a dimer comprising two receptor molecules bound to a single molecule of VEGF.

The term "epitope A4.6.1" when used herein, unless indicated otherwise, refers to the region of human VEGF to which the A4.6.1 antibody disclosed in Kim *et al.*, *Growth Factors* 7:53 (1992) and Kim *et al.* Nature 362:841 (1993), binds.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, *etc.* Preferably, the mammal is human.

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

"Native antibodies" and "native immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V_H) followed by a number of constant domains. Each light chain has a variable domain at one end (V_L) and a constant domain at its other end; the

constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light- chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.

5

10

The same of given they of the same than the

25

30

The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework region (FR). The variable domains of native heavy and light chains each comprise four FRs (FR1, FR2, FR3 and FR4, respectively), largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991), pages 647-669). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (*i.e.* residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat *et al.*, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (*i.e.* residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk *J. Mol. Biol.* 196:901-917 (1987)). "Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.

10

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')₂ fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the V_H - V_L dimer. Collectively, the six hypervariable regions confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteine(s) from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')₂ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ε , γ , and μ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

25

30

5

10

The term "antibody" herein is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.

"Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.*, *Nature* 256:495 (1975), or may be made by recombinant DNA methods (see, *e.g.*, U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, *Nature* 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.* 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci.

USA 81:6851-6855 (1984)).

5

10

25

30

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Reichmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

"Single-chain Fv" or "sFv" antibody fragments comprise the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V_H) connected to a light chain variable domain (V_L) in the same polypeptide chain (V_H - V_L). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993).

The expression "linear antibodies" when used throughout this application refers to the antibodies described in Zapata *et al. Protein Eng.* 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V_H-C_H1-V_H-C_H1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

5

10

The state of the s

25

30

A "variant" anti-VEGF antibody, refers herein to a molecule which differs in amino acid sequence from a "parent" anti-VEGF antibody amino acid sequence by virtue of addition, deletion and/or substitution of one or more amino acid residue(s) in the parent antibody sequence. In the preferred embodiment, the variant comprises one or more amino acid substitution(s) in one or more hypervariable region(s) of the parent antibody. For example, the variant may comprise at least one, e.g. from about one to about ten, and preferably from about two to about five, substitutions in one or more hypervariable regions of the parent antibody. Ordinarily, the variant will have an amino acid sequence having at least 75% amino acid sequence identity with the parent antibody heavy or light chain variable domain sequences (e.g. as in SEQ ID NO:7 or 8), more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. Identity or homology with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the parent antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence shall be construed as affecting sequence identity or homology. The variant retains the ability to bind human VEGF and preferably has properties which are superior to those of the parent antibody. For example, the variant may have a stronger binding affinity, enhanced ability to inhibit VEGF-induced proliferation of endothelial cells and/or increased ability to inhibit VEGF-induced angiogenesis in vivo. To analyze such properties, one should compare a Fab form of the variant to a Fab form of the parent antibody or a full length form of the variant to a full length form of the parent antibody, for example, since it has been found that the format of the anti-VEGF antibody impacts its activity in the biological activity assays disclosed herein. The variant antibody of particular interest herein is one which displays at least about 10 fold, preferably at least about 20 fold, and most preferably at least about 50 fold, enhancement in biological activity when compared to the parent antibody.

The "parent" antibody herein is one which is encoded by an amino acid sequence used for

the preparation of the variant. Preferably, the parent antibody has a human framework region and, if present, has human antibody constant region(s). For example, the parent antibody may be a humanized or human antibody.

5

10

The said that the

: da

ļ. **2**

and and

25

30

20

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody *in situ* within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

The term "epitope tagged" when used herein refers to the anti-VEGF antibody fused to an "epitope tag". The epitope tag polypeptide has enough residues to provide an epitope against which an antibody thereagainst can be made, yet is short enough such that it does not interfere with activity of the VEGF antibody. The epitope tag preferably is sufficiently unique so that the antibody thereagainst does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least 6 amino acid residues and usually between about 8-50 amino acid residues (preferably between about 9-30 residues). Examples include the flu HA tag polypeptide and its antibody 12CA5 (Field *et al. Mol. Cell. Biol.* 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan *et al., Mol. Cell. Biol.* 5(12):3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky *et al., Protein Engineering* 3(6):547-553 (1990)). In certain embodiments, the epitope tag is a "salvage receptor binding epitope". As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (*e.g.,* IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the

30

5

10

function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (*e.g.*, I¹³¹, I ¹²⁵, Y ⁹⁰ and Re ¹⁸⁶), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Taxotere (docetaxel), Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan and other related nitrogen mustards.

The term "prodrug" as used in this application refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, e.g., Wilman, "Prodrugs in Cancer Chemotherapy" *Biochemical Society Transactions*, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella *et al.*, "Prodrugs: A Chemical Approach to Targeted Drug Delivery," *Directed Drug Delivery*, Borchardt *et al.*, (ed.), pp. 247-267, Humana Press (1985). The prodrugs of this invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, O-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs. Examples of cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, those chemotherapeutic agents described above.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody. The label may itself be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed

30

5

10

partially or entirely of glass (e.g. controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g. an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as the anti-VEGF antibodies disclosed herein and, optionally, a chemotherapeutic agent) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The expression "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by

ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

II. Modes for Carrying out the Invention

5

10

25

30

(KaleidaGraph).

20

The examples hereinbelow describe the production of humanized and variant anti-VEGF antibodies with desirable properties from a therapeutic perspective including: (a) strong binding affinity for the VEGF antigen; (b) an ability to inhibit VEGF-induced proliferation of endothelial cells in vitro; and (c) the ability to inhibit VEGF-induced angiogenesis in vivo.

Antibody affinities may be determined as described in the examples hereinbelow. Preferred humanized or variant antibodies are those which bind human VEGF with a K_d value of no more than about 1 x 10^{-7} M; preferably no more than about 1 x 10^{-8} M; and most preferably no more than about 5 x 10^{-9} M.

Aside from antibodies with strong binding affinity for human VEGF, it is also desirable to select humanized or variant antibodies which have other beneficial properties from a therapeutic perspective. For example, the antibody may be one which inhibits endothelial cell growth in response to VEGF. In one embodiment, the antibody may be able to inhibit bovine capillary endothelial cell proliferation in response to a near maximally effective concentration of VEGF (3 ng/ml). Preferably, the antibody has an effective dose 50 (ED50) value of no more than about 5nM, preferably no more than about 1nM, and most preferably no more than about 0.5nM, for inhibiting VEGF-induced proliferation of endothelial cells in this "endothelial cell growth assay", i.e., at these concentrations the antibody is able to inhibit VEGF-induced endothelial cell growth in vitro by 50%. A preferred "endothelial cell growth assay" involves culturing bovine adrenal cortexderived capillary endothelial cells in the presence of low glucose Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10% calf serum, 2 mM glutamine, and antibiotics (growth medium), essentially as described in Example 1 below. These endothelial cells are seeded at a density of 6 x 10³ cells per well, in 6-well plates in growth medium. Either parent anti-VEGF antibody (control), humanized or variant anti-VEGF antibody is then added at concentrations ranging between 1 and 5000 ng/ml. After 2-3 hr, purified VEGF was added to a final concentration of 3 ng/ml. For specificity control, each antibody may be added to endothelial cells at the concentration of 5000 ng/ml, either alone or in the presence of 2 ng/ml bFGF. After five or six days, cells are dissociated by exposure to trypsin and counted in a Coulter counter (Coulter Electronics, Hialeah, FL). Data may be analyzed by a four-parameter curve fitting program tumor suppression activity. For example, the antibody may also be one which has *in vivo* tumor suppression activity. For example, the antibody may suppress the growth of human A673 rhabdomyosarcoma cells or breast carcinoma MDA-MB-435 cells in nude mice. For *in vivo* tumor studies, human A673 rhabdomyosarcoma cells (ATCC; CRL 1598) or MDA-MB-435 cells (available from the ATCC) are cultured in DMEM/F12 supplemented with 10% fetal bovine serum, 2 mM glutamine and antibiotics as described in Example 1 below. Female BALB/c nude mice, 6-10 weeks old, are injected subcutaneously with 2 x 10⁶ tumor cells in the dorsal area in a volume of 200 µl. Animals are then treated with the humanized or variant antibody and a control antibody with no activity in this assay. The humanized or variant anti-VEGF MAb is administered at a dose of 0.5 and/or 5 mg/kg. Each MAb is administered twice weekly intra peritoneally in a volume of 100 µl, starting 24 hr after tumor cell inoculation. Tumor size is determined at weekly intervals. Four weeks after tumor cell inoculation, animals are euthanized and the tumors are removed and weighed. Statistical analysis may be performed by ANOVA. Preferably, the antibody in this "*in vivo* tumor assay" inhibits about 50-100%, preferably about 70-100% and most preferably about 80-100% human A673 tumor cell growth at a dose of 5mg/kg.

In the preferred embodiment, the humanized or variant antibody fails to elicit an immunogenic response upon administration of a therapeutically effective amount of the antibody to a human patient. If an immunogenic response is elicited, preferably the response will be such that the antibody still provides a therapeutic benefit to the patient treated therewith.

The humanized or variant antibody is also preferably one which is able to inhibit VEGF-induced angiogenesis in a human, *e.g.* to inhibit human tumor growth and/or inhibit intraocular angiogenesis in retinal disorders.

Preferred antibodies bind the "epitope A4.6.1" as herein defined. To screen for antibodies which bind to the epitope on human VEGF bound by an antibody of interest (*e.g.*, those which block binding of the A4.6.1 antibody to human VEGF), a routine cross-blocking assay such as that described in *Antibodies*, *A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping, *e.g.* as described in Champe *et al.*, *J. Biol. Chem.* 270:1388-1394 (1995), can be performed to determine whether the antibody binds an epitope of interest.

5

10

j. 4

į .

20

25

10

The antibodies of the preferred embodiment herein have a heavy chain variable domain comprising an amino acid sequence represented by the formula: FR1-CDRH1-FR2-CDRH2-FR3-CDRH3-FR4, wherein "FR1-4" represent the four framework regions and "CDRH1-3" represent the three hypervariable regions of an anti-VEGF antibody variable heavy domain. FR1-4 may be derived from a "consensus sequence" (*i.e.* the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) as in the examples below or may be derived from an individual human antibody framework region or from a combination of different framework region sequences. Many human antibody framework region sequences are compiled in Kabat *et al.*, *supra*, for example. In one preferred embodiment, the variable heavy FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat *et al.*, *supra*. Preferably, the human immunoglobulin subgroup is human heavy chains subgroup III (*e.g.* as in SEQ ID NO:11).

The human variable heavy FR sequence preferably has substitutions therein, *e.g.* wherein the human FR residue is replaced by a corresponding nonhuman residue (by "corresponding nonhuman residue" is meant the nonhuman residue with the same Kabat positional numbering as the human residue of interest when the human and nonhuman sequences are aligned), but replacement with the nonhuman residue is not necessary. For example, a replacement FR residue other than the corresponding nonhuman residue may be selected by phage display (see Example 2 below). Exemplary variable heavy FR residues which may be substituted include any one or more of FR residue numbers: 37H, 49H, 67H, 69H, 71H, 73H, 75H, 76H, 78H, 94H (Kabat residue numbering employed here). Preferably at least two, or at least three, or at least four of these residues are substituted. A particularly preferred combination of FR substitutions is: 49H, 69H, 71H, 73H, 76H, 78H, and 94H.

With respect to the heavy chain hypervariable regions, these preferably have amino acid sequences as follows:

CDRH1

 $GYX_1X_2X_3X_4YGX_5N$ (SEQ ID NO:117), wherein X_1 is D, T or E, but preferably is D or T; X_2 is F, W, or Y, but preferably is F; X_3 is T, Q, G or S, but preferably is T; X_4 is H or N; and X_5 is M or I, but preferably is M.

25

CDRH2

WINTX₁TGEPTYAADFKR (SEQ ID NO:118), wherein X₁ is Y or W, but preferably is Y.

CDRH3

5

10

The second

. .

į.

25

30

 $YPX_1YX_2X_3X_4X_5HWYFDV$ (SEQ ID NO:119), wherein X_1 is H or Y; X_2 is Y, R, K, I, T, E, or W, but preferably is Y; X_3 is G, N, A, D, Q, E, T, K, or S, but preferably is G; X_4 is S, T, K, Q, N, R, A, E, or G, but preferably is S or T; and X_5 is S or G, but preferably is S.

The heavy chain variable domain optionally comprises what has been designated "CDR7" herein within (*i.e.* forming part of) FR3 (see Figs. 9B and 10B), wherein CDR7 may have the following amino acid sequence:

CDR7

 $X_1SX_2DX_3X_4X_5X_6TX_7$ (SEQ ID NO:120), wherein X_1 is F, I, V, L, or A, but preferably is F; X_2 is A, L, V, or I, but preferably is L; X_3 is T, V or K, but preferably is T; X_4 is S or W, but preferably is S; X_5 is S, or K, but preferably is K; X_6 is N, or S, but preferably is S; and X_7 is V, A, L or I, but preferably is A.

The antibodies of the preferred embodiment herein have a light chain variable domain comprising an amino acid sequence represented by the formula: FR1-CDRL1-FR2-CDRL2-FR3-CDRL3-FR4, wherein "FR1-4" represent the four framework regions and "CDRL1-3" represent the three hypervariable regions of an anti-VEGF antibody variable heavy domain. FR1-4 may be derived from a "consensus sequence" (i.e. the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) as in the examples below or may be derived from an individual human antibody framework region or from a combination of different framework region sequences. In one preferred embodiment, the variable light FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat *et al.*, *supra*. Preferably, the human immunoglobulin subgroup is human kappa light chains subgroup I (*e.g.* as in SEQ ID NO:12).

The human variable light FR sequence preferably has substitutions therein, e.g. wherein the

human FR residue is replaced by a corresponding mouse residue, but replacement with the nonhuman residue is not necessary. For example, a replacement residue other than the corresponding nonhuman residue may be selected by phage display (see Example 2 below). Exemplary variable light FR residues which may be substituted include any one or more of FR residue numbers: 4L, 46L and 71L (Kabat residue numbering employed here). Preferably only 46L is substituted. In another embodiment, both 4L and 46L are substituted.

With respect to the CDRs, these preferably have amino acid sequences as follows: CDRL1

 $X_1AX_2X_3X_4X_5SNYLN$ (SEQ ID NO:121), wherein X_1 is R or S, but preferably is S; X_2 is S or N, but preferably is S; X_3 is Q or E, but preferably is Q; X_4 is Q or D, but preferably is D; and X_5 is I or L, but preferably is I.

CDRL2

5

10

The state of the s

25

30

FTSSLHS (SEQ ID NO:122).

CDRL3

QQYSX₁X₂PWT (SEQ ID NO:123), wherein X_1 is T, A or N, but preferably is T; and X_2 is V or T, but preferably is V.

Preferred humanized anti-VEGF antibodies are those having the heavy and/or light variable domain sequences of F(ab)-12 in Example 1 and variants thereof such as affinity matured forms including variants Y0317, Y0313-1 and Y0238-3 in Example 3, with Y0317 being the preferred variant. Methods for generating humanized anti-VEGF antibodies of interest herein are elaborated in more detail below.

A. Antibody Preparation

Methods for humanizing nonhuman VEGF antibodies and generating variants of anti-VEGF antibodies are described in the examples below. In order to humanize an anti-VEGF antibody, the nonhuman antibody starting material is prepared. Where a variant is to be generated, the parent antibody is prepared. Exemplary techniques for generating such nonhuman antibody

starting material and parent antibodies will be described in the following sections.

(i) Antigen preparation

5

10

The Heav

î.

į. 45.

ļ. **4**

25

30

15

The VEGF antigen to be used for production of antibodies may be, e.g., intact VEGF or a fragment of VEGF (e.g. a VEGF fragment comprising "epitope A4.6.1"). Other forms of VEGF useful for generating antibodies will be apparent to those skilled in the art. The VEGF antigen used to generate the antibody, is preferably human VEGF, e.g. as described in Leung et al., Science 246:1306 (1989), and Houck et al., Mol. Endocrin. 5:1806 (1991).

(ii) Polyclonal antibodies

Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl₂, or R¹N=C=NR, where R and R¹ are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 µg or 5 µg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

(iii) Monoclonal antibodies

Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

5

10

ij

25

30

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and M.C.-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al., Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard

į, 21.

20

25

30

5

methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.

(iv) Humanization and amino acid sequence variants

Examples 1-2 below describe procedures for humanization of an anti-VEGF antibody. In certain embodiments, it may be desirable to generate amino acid sequence variants of these humanized antibodies, particularly where these improve the binding affinity or other biological properties of the humanized antibody. Example 3 describes methodologies for generating amino acid sequence variants of an anti-VEGF antibody with enhanced affinity relative to the parent antibody.

Amino acid sequence variants of the anti-VEGF antibody are prepared by introducing appropriate nucleotide changes into the anti-VEGF antibody DNA, or by peptide synthesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-VEGF antibodies of the examples herein. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the humanized or variant anti-VEGF antibody, such as changing the number or position of glycosylation sites.

10

A useful method for identification of certain residues or regions of the anti-VEGF antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells *Science*, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with VEGF antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed anti-VEGF antibody variants are screened for the desired activity. Alanine scanning mutagenesis is described in Example 3.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an anti-VEGF antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants of the anti-VEGF antibody molecule include the fusion to the N- or C-terminus of the anti-VEGF antibody of an enzyme or a polypeptide which increases the serum half-life of the antibody (see below).

Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the anti-VEGF antibody molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table 1, or as further described below in reference to amino acid classes, may be introduced and the products screened.

25

Table 1

Original Exemplary Preferred **Substitutions** Residue **Substitutions** val; leu; ile val Ala (A) lys lys; gln; asn Arg (R) gln gln; his; asp, lys; Asn (N) arg glu glu; asn Asp (D) ser; ala ser Cys (C) Gln (Q) asn; glu asn asp Glu (E) asp; gln ala Gly (G) ala His (H) asn; gln; lys; arg arg leu leu; val; met; ala; lle (I) phe; norleucine norleucine; ile; val; ile Leu (L) met; ala; phe arg; gln; asn Lys (K) arg Met (M) leu; phe; ile leu Phe (F) leu; val; ile; ala; tyr tyr Pro (P) ala ala Ser (S) thr thr Thr (T) ser ser Trp (W) tyr; phe tyr trp; phe; thr; ser phe Tyr (Y) ile; leu; met; phe; leu Val (V) ala; norleucine

5

10

20

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

5

10

1,45

į, di

The same of the same

25

30

(4) basic: asn, gln, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the humanized or variant anti-VEGF antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display (see Example 3 herein). Briefly, several hypervariable region sites (e.g. 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis (see Example 3) can be performed

10

to identified hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigenantibody complex to identify contact points between the antibody and human VEGF. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.

Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

Nucleic acid molecules encoding amino acid sequence variants of the anti-VEGF antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-VEGF antibody.

25

(v) Human antibodies

5

10

Ann and And Hall

١,٠٠٠

\$.F\$

Į.

ļ. **4**.

25

30

As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (*e.g.*, mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, *e.g.*, Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits *et al.*, *Nature*, 362:255-258 (1993); Bruggermann *et al.*, *Year in Immuno.*, 7:33 (1993); and US Patents 5,591,669, 5,589,369 and 5,545,807. Human antibodies can also be derived from phage-display libraries (Hoogenboom *et al.*, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991); and US Patents 5,565,332 and 5,573,905). As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see US Patents 5,567,610 and 5,229,275)

(vi) Antibody fragments

In certain embodiments, the humanized or variant anti-VEGF antibody is an antibody fragment. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')₂ fragments (Carter et al., Bio/Technology 10:163-167 (1992)). In another embodiment, the F(ab')₂ is formed using the leucine zipper GCN4 to promote assembly of the F(ab')₂ molecule. According to another approach, Fv, Fab or F(ab')₂ fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.

(vii) Multispecific antibodies

In some embodiments, it may be desirable to generate multispecific (e.g. bispecific) humanized or variant anti-VEGF antibodies having binding specificities for at least two different

epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the VEGF protein. Alternatively, an anti-VEGF arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2 or CD3), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRII (CD16) so as to focus cellular defense mechanisms to the VEGF-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express VEGF. These antibodies possess an VEGF-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')₂ bispecific antibodies).

5

10

The state of the s

1.4

. **2**.

25

30

According to another approach for making bispecific antibodies, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C_H3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. See WO96/27011 published September 6, 1996.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to

30

5

10

thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. In yet a further embodiment, Fab'-SH fragments directly recovered from *E. coli* can be chemically coupled *in vitro* to form bispecific antibodies. Shalaby *et al.*, *J. Exp. Med.* 175:217-225 (1992).

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_L) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the $V_{\scriptscriptstyle H}$ and $V_{\scriptscriptstyle L}$ domains of one fragment are forced to pair with the complementary $V_{\scriptscriptstyle L}$ and $V_{\scriptscriptstyle H}$ domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol. 152:5368 (1994). Alternatively, the bispecific antibody may be a "linear antibody" produced as described in Zapata et al. Protein Eng. 8(10):1057-1062 (1995).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

(viii) Other modifications

Other modifications of the humanized or variant anti-VEGF antibody are contemplated. For example, it may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example. For example cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain

30

5

10

disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989).

The invention also pertains to immunoconjugates comprising the antibody described herein conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated anti-VEGF antibodies. Examples include ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y and ¹⁸⁶Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl)hexanediamine), bis-diazoniumderivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an

exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radionuclide).

5

10

Ann The Ant Ant

, Jul 10.

II.

25

30

The anti-VEGF antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, *Proc. Natl. Acad. Sci. USA* 82:3688 (1985); Hwang *et al.*, *Proc. Natl Acad. Sci. USA* 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, *J. Biol. Chem.* 257:286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, *J. National Cancer Inst.*81(19):1484 (1989)

The antibody of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.

The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases,

30

5

10

such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β -galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; β -lactamase useful for converting drugs derivatized with β -lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328:457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.

The enzymes of this invention can be covalently bound to the anti-VEGF antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, *e.g.*, Neuberger *et al.*, *Nature* 312:604-608 (1984)).

In certain embodiments of the invention, it may be desirable to use an antibody fragment, rather than an intact antibody, to increase tumor penetration, for example. In this case, it may be desirable to modify the antibody fragment in order to increase its serum half life. This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody fragment (e.g., by mutation of the appropriate region in the antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at either end or in the middle, e.g., by DNA or peptide synthesis). See WO96/32478 published October 17, 1996.

The salvage receptor binding epitope generally constitutes a region wherein any one or more amino acid residues from one or two loops of a Fc domain are transferred to an analogous position of the antibody fragment. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e.g., of an IgG) and transferred to the CH1, CH3, or V_H region, or more than one such region, of the antibody. Alternatively, the epitope is taken from the CH2 domain

of the Fc region and transferred to the C_L region or V_L region, or both, of the antibody fragment.

In one most preferred embodiment, the salvage receptor binding epitope comprises the sequence: PKNSSMISNTP (SEQ ID NO:17), and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO:18), HQNLSDGK (SEQ ID NO:19), HQNISDGK (SEQ ID NO:20), or VISSHLGQ (SEQ ID NO:21), particularly where the antibody fragment is a Fab or F(ab')₂. In another most preferred embodiment, the salvage receptor binding epitope is a polypeptide containing the sequence(s): HQNLSDGK (SEQ ID NO:19), HQNISDGK (SEQ ID NO:20), or VISSHLGQ (SEQ ID NO:21) and the sequence: PKNSSMISNTP (SEQ ID NO:17).

Covalent modifications of the humanized or variant anti-VEGF antibody are also included within the scope of this invention. They may be made by chemical synthesis or by enzymatic or chemical cleavage of the antibody, if applicable. Other types of covalent modifications of the antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues. Exemplary covalent modifications of polypeptides are described in US Patent 5,534,615, specifically incorporated herein by reference. A preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

B. Vectors, Host Cells and Recombinant Methods

5

10

15

1.71

The His

25

30

The invention also provides isolated nucleic acid encoding the humanized or variant anti-VEGF antibody, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody.

For recombinant production of the antibody, the nucleic acid encoding it may be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. In another embodiment, the antibody may be produced by homologous recombination, *e.g.* as described in US Patent 5,204,244, specifically incorporated herein by reference. DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components

generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, *e.g.*, as described in US Patent 5,534,615 issued July 9, 1996 and specifically incorporated herein by reference.

5

10

1**1**5

å. **±**

]; **2**

25

30

Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-VEGF antibody-encodingvectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe*; *Kluyveromyces* hosts such as, e.g., *K. lactis*, *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilarum* (ATCC 36,906), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa*; *Schwanniomyces* such as *Schwanniomyces occidentalis*; and filamentous fungi such as, e.g., *Neurospora, Penicillium*, *Tolypocladium*, and *Aspergillus* hosts such as *A. nidulans* and *A. niger*.

Suitable host cells for the expression of glycosylated anti-VEGF antibody are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains

30

5

10

for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al., J. Gen Virol.* 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub *et al., Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather *et al., Annals N.Y. Acad. Sci.* 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors for anti-VEGF antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

The host cells used to produce the anti-VEGF antibody of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham *et al.*, *Meth. Enz.* 58:44 (1979), Barnes *et al.*, *Anal. Biochem.*102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and

30

5

10

phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter *et al.*, *Bio/Technology* 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of *E. coli.* Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human γ1, γ2, or γ4 heavy chains (Lindmark *et al., J. Immunol. Meth.* 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human γ3 (Guss *et al., EMBO J.* 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzeneallow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a C_H3 domain, the Bakerbond ABXTMresin

30

5

10

(J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).

C. Pharmaceutical Formulations

Therapeutic formulations of the antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other (see Section F below). Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

5

10

hore can be give the first flow that

į, 4.

25

30

The active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethylmethacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of Lglutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

D. Non-therapeutic Uses for the Antibody

The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing

30

5

10

the VEGF protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the VEGF protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the VEGF protein from the antibody.

Anti-VEGF antibodies may also be useful in diagnostic assays for VEGF protein, e.g., detecting its expression in specific cells, tissues, or serum. Such diagnostic methods may be useful in cancer diagnosis.

For diagnostic applications, the antibody typically will be labeled with a detectable moiety. Numerous labels are available which can be generally grouped into the following categories:

- (a) Radioisotopes, such as ³⁵S, ¹⁴C, ¹²⁵I, ³H, and ¹³¹I. The antibody can be labeled with the radioisotope using the techniques described in *Current Protocols in Immunology*, Volumes 1 and 2, Coligen *et al.*, Ed. Wiley-Interscience, New York, New York, Pubs. (1991) for example and radioactivity can be measured using scintillation counting.
- (b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin and Texas Red are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in *Current Protocols in Immunology*, *supra*, for example. Fluorescence can be quantified using a fluorimeter.
- (c) Various enzyme-substrate labels are available and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme generally catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish

30

5

10

peroxidase (HRPO), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan *et al.*, Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in *Methods in Enzym.* (ed J. Langone & H. Van Vunakis), Academic press, New York, 73:147-166 (1981).

Examples of enzyme-substrate combinations include, for example:

- (i) Horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));
- (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and
- (iii) β -D-galactosidase (β -D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- β -D-galactosidase) or fluorogenic substrate 4-methylumbelliferyl- β -D-galactosidase.

Numerous other enzyme-substrate combinations are available to those skilled in the art. For a general review of these, see U.S. Patent Nos. 4,275,149 and 4,318,980.

Sometimes, the label is indirectly conjugated with the antibody. The skilled artisan will be aware of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or *vice versa*. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved.

In another embodiment of the invention, the anti-VEGF antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the VEGF antibody.

The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp.147-158 (CRC Press, Inc.

10

Sant on a contract of man

ΪIJ

1 1

20

1

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of VEGF protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., US Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulinantibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

The antibodies may also be used for *in vivo* diagnostic assays. Generally, the antibody is labeled with a radio nuclide (such as ¹¹¹In, ⁹⁹Tc, ¹⁴C, ¹³¹I, ¹²⁵I, ³H, ³²P or ³⁵S) so that the tumor can be localized using immunoscintiography.

E. Diagnostic Kits

As a matter of convenience, the antibody of the present invention can be provided in a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay. Where the antibody is labeled with an enzyme, the kit will include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer) and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay. Particularly, the reagents may be provided

25

as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

F. Therapeutic Uses for the Antibody

5

10

į **1**

25

30

20

For therapeutic applications, the anti-VEGF antibodies of the invention are administered to a mammal, preferably a human, in a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. The antibodies also are suitably administered by intra tumoral, peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route is expected to be particularly useful, for example, in the treatment of ovarian tumors.

For the prevention or treatment of disease, the appropriate dosage of antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments.

The anti-VEGF antibodies are useful in the treatment of various neoplastic and non-neoplastic diseases and disorders. Neoplasms and related conditions that are amenable to treatment include breast carcinomas, lung carcinomas, gastric carcinomas, esophageal carcinomas, colorectal carcinomas, liver carcinomas, ovarian carcinomas, thecomas, arrhenoblastomas, cervical carcinomas, endometrial carcinoma, endometrial hyperplasia, endometriosis, fibrosarcomas, choriocarcinoma, head and neck cancer, nasopharyngeal carcinoma, laryngeal carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma, skin carcinomas, hemangioma, cavernous hemangioma, hemangioblastoma, pancreas carcinomas, retinoblastoma, astrocytoma, glioblastoma, Schwannoma, oligodendroglioma, medulloblastoma, neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma, leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas, Wilm's tumor, renal cell carcinoma, prostate carcinoma, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome.

30

5

10

Non-neoplastic conditions that are amenable to treatment include rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other proliferative retinopathies including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, chronic inflammation, lung inflammation, nephrotic syndrome, preeclampsia, ascites, pericardial effusion (such as that associated with pericarditis), and pleural effusion.

Age-related macular degeneration (AMD) is a leading cause of severe visual loss in the elderly population. The exudative form of AMD is characterized by choroidal neovascularization and retinal pigment epithelial cell detachment. Because choroidal neovascularization is associated with a dramatic worsening in prognosis, the VEGF antibodys of the present invention are expected to be especially useful in reducing the severity of AMD.

Depending on the type and severity of the disease, about 1 µg/kg to about 50 mg/kg (e.g., 0.1-20mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily or weekly dosage might range from about 1 µg/kg to about 20 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic tumor imaging.

According to another embodiment of the invention, the effectiveness of the antibody in preventing or treating disease may be improved by administering the antibody serially or in combination with another agent that is effective for those purposes, such as tumor necrosis factor (TNF), an antibody capable of inhibiting or neutralizing the angiogenic activity of acidic or basic fibroblast growth factor (FGF) or hepatocyte growth factor (HGF), an antibody capable of inhibiting or neutralizing the coagulant activities of tissue factor, protein C, or protein S (see Esmon et al., PCT Patent Publication No. WO 91/01753, published 21 February 1991), an antibody capable of binding to HER2 receptor (see Hudziak et al., PCT Patent Publication No. WO 89/06692, published 27 July 1989), or one or more conventional therapeutic agents such as, for example, alkylating agents, folic acid antagonists, anti-metabolites of nucleic acid metabolism, antibiotics,

30

5

10

pyrimidine analogs, 5-fluorouracil, cisplatin, purine nucleosides, amines, amino acids, triazol nucleosides, or corticosteroids. Such other agents may be present in the composition being administered or may be administered separately. Also, the antibody is suitably administered serially or in combination with radiological treatments, whether involving irradiation or administration of radioactive substances.

In one embodiment, vascularization of tumors is attacked in combination therapy. The antibody and one or more other anti-VEGF antagonists are administered to tumor-bearing patients at therapeutically effective doses as determined for example by observing necrosis of the tumor or its metastatic foci, if any. This therapy is continued until such time as no further beneficial effect is observed or clinical examination shows no trace of the tumor or any metastatic foci. Then TNF is administered, alone or in combination with an auxiliary agent such as alpha-, beta-, or gamma-interferon, anti-HER2 antibody, heregulin, anti-heregulin antibody, D-factor, interleukin-1 (IL-1), interleukin-2 (IL-2), granulocyte-macrophage colony stimulating factor (GM-CSF), or agents that promote microvascular coagulation in tumors, such as anti-protein C antibody, anti-protein S antibody, or C4b binding protein (see Esmon et al., PCT Patent Publication No. WO 91/01753, published 21 February 1991), or heat or radiation.

Since the auxiliary agents will vary in their effectiveness it is desirable to compare their impact on the tumor by matrix screening in conventional fashion. The administration of anti-VEGF antibody and TNF is repeated until the desired clinical effect is achieved. Alternatively, the anti-VEGF antibody is administered together with TNF and, optionally, auxiliary agent(s). In instances where solid tumors are found in the limbs or in other locations susceptible to isolation from the general circulation, the therapeutic agents described herein are administered to the isolated tumor or organ. In other embodiments, a FGF or platelet-derived growth factor (PDGF) antagonist, such as an anti-FGF or an anti-PDGF neutralizing antibody, is administered to the patient in conjunction with the anti-VEGF antibody. Treatment with anti-VEGF antibodies optimally may be suspended during periods of wound healing or desirable neovascularization.

G. Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials,

30

5

10

syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the anti-VEGF antibody. The label on, or associated with, the container indicates that the composition is used for treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

EXAMPLE 1

This example describes the production of humanized anti-VEGF antibodies with desirable properties from a therapeutic standpoint.

MATERIALS AND METHODS

Cloning of Murine A4.6.1 MAb and Construction of Mouse-Human Chimeric Fab: The murine anti-VEGF mAb A4.6.1 has been previously described by Kim et al., Growth Factors 7:53 (1992) and Kim et al. Nature 362:841 (1993). Total RNA was isolated from hybridoma cells producing the anti-VEGF Mab A.4.6.1 using RNAsol (TEL-TEST) and reverse-transcribed to cDNA using Oligo-dT primer and the SuperScript II system (GIBCO BRL, Gaithersburg, MD). Degenerate oligonucleotide primer pools, based of the N-terminal amino acid sequences of the light and heavy chains of the antibody, were synthesized and used as forward primers. Reverse primers were based on framework 4 sequences obtained from murine light chain subgroup kV and heavy chain subgroup II (Kabat et al. Sequences of Proteins of Immunological Interest. 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). After polymerase chain reaction (PCR) amplification, DNA fragments were ligated to a TA cloning vector (Invitrogen, San Diego, CA). Eight clones each of the light and heavy chains were sequenced. One clone with a consensus sequence for the light chain VL domain and one with a consensus sequence for the heavy chain VH domain were subcloned respectively into the pEMX1 vector containing the human CL and CH1 domains (Werther et al. J. Immunol. 157:4986-4995 (1996)), thus generating a

25

30

5

mouse-human chimera. This chimeric F(ab) consisted of the entire murine A4.6.1 VH domain fused to a human CH1 domain at amino acid SerH113 and the entire murine A4.6.1 VL domain fused to a human CL domain at amino acid LysL107. Expression and purification of the chimeric F(ab) were identical to that of the humanized F(ab)s. The chimeric F(ab) was used as the standard in the binding assays.

Computer Graphics Models of Murine and Humanized F(ab): Sequences of the VL and VH domains (Figs.1A and 1B) were used to construct a computer graphics model of the murine A4.6.1 VL-VH domains. This model was used to determine which framework residues should be incorporated into the humanized antibody. A model of the humanized F(ab) was also constructed to verify correct selection of murine framework residues. Construction of models was performed as described previously (Carter et al. Proc. Natl. Acad. Sci. USA 89:4285-4289 (1992) and Eigenbrot et al. J.Mol. Biol. 229:969-995 (1993)).

Construction of Humanized F(ab)s: The plasmid pEMX1 used for mutagenesis and expression of F(ab)s in E. coli has been described previously (Werther et al., supra). Briefly, the plasmid contains a DNA fragment encoding a consensus human k subgroup I light chain (VLkI-CL) and a consensus human subgroup III heavy chain (VHIII-CH1) and an alkaline phosphatase promoter. The use of the consensus sequences for VL and VH has been described previously (Carter et al., supra).

To construct the first F(ab) variant of humanized A4.6.1, F(ab)-1, site-directed mutagenesis (Kunkel *et al.*, *Proc. Natl. Acad. Sci. USA* 82:488-492 (1985)) was performed on a deoxyuridine-containing template of pEMX1. The six CDRs according to Kabat *et al.*, *supra*, were changed to the murine A4.6.1 sequence . F(ab)-1 therefore consisted of a complete human framework (VL k subgroup I and VH subgroup III) with the six complete murine CDR sequences. Plasmids for all other F(ab) variants were constructed from the plasmid template of F(ab)-1. Plasmids were transformed into *E. coli* strain XL-1 Blue (Stratagene, San Diego, CA) for preparation of double-and single-stranded DNA. For each variant, DNA coding for light and heavy chains was completely sequenced using the dideoxynucleotide method (Sequenase, U.S. Biochemical Corp., Cleveland, OH). Plasmids were transformed into *E. coli* strain 16C9, a derivative of MM294, plated onto Luria broth plates containing 50 μg/ml carbenicillin, and a single colony selected for protein expression. The single colony was grown in 5 ml Luria broth-100 mg/ml carbenicillin for

5-8 h at 37° C. The 5 ml culture was added to 500 ml AP5-50 μg/ml carbenicillin and allowed to grow for 20 h in a 4 L baffled shake flask at 30° C. AP5 media consists of: 1.5 g glucose, 11.0 g Hycase SF, 0.6 g yeast extract (certified), 0.19 g MgSO4 (anhydrous), 1.07 g NH4Cl, 3.73 g KCl, 1.2 g NaCl, 120 ml 1 M triethanolamine, pH 7.4, to 1 L water and then sterile filtered through 0.1 mm Sealkeen filter. Cells were harvested by centrifugation in a 1 L centrifuge bottle at 3000xg and the supernatant removed. After freezing for 1 h, the pellet was resuspended in 25 ml cold 10 mM Tris-1 mM EDTA-20% sucrose, pH 8.0. 250 ml of 0.1 M benzamidine (Sigma, St. Louis, MO) was added to inhibit proteolysis. After gentle stirring on ice for 3 h, the sample was centrifuged at 40,000xg for 15 min. The supernatant was then applied to a protein G-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) column (0.5 ml bed volume) equilibrated with 10 mM Tris-1 mM EDTA, pH 7.5. The column was washed with 10 ml of 10 mM Tris-1 mM EDTA, pH 7.5, and eluted with 3 ml 0.3 M glycine, pH 3.0, into 1.25 ml 1 M Tris, pH 8.0. The F(ab) was then buffer exchanged into PBS using a Centricon-30 (Amicon, Beverly, MA) and concentrated to a final volume of 0.5 ml. SDS-PAGE gels of all F(ab)s were run to ascertain purity and the molecular weight of each variant was verified by electrospray mass spectrometry.

Construction and Expression of Chimeric and Humanized IgG: For generation of human IgG1 variants of chimeric (chlgG1) and humanized (hulgG1) A4.6.1, the appropriate murine or humanized VL and VH (F(ab)-12, Table 2) domains were subcloned into separate, previously described, pRK vectors (Eaton et al., Biochemistry 25:8343-8347 (1986)). The DNA coding for the entire light and the entire heavy chain of each variant was verified by dideoxynucleotide sequencing.

For transient expression of variants, heavy and light chain plasmids were co-transfected into human 293 cells (Graham *et al.*, *J. Gen. Virol.* 36:59-74 (1977)), using a high efficiency procedure (Gorman *et al.*, *DNA Prot. Eng. Tech.* 2:3-10 (1990)). Media was changed to serum-free and harvested daily for up to five days. Antibodies were purified from the pooled supernatants using protein A-Sepharose CL-4B (Pharmacia). The eluted antibody was buffer exchanged into PBS using a Centricon-30 (Amicon), concentrated to 0.5 ml, sterile filtered using a Millex-GV (Millipore, Bedford, MA) and stored at 4°C.

30

5

10

For stable expression of the final humanized IgG1 variant (rhuMAb VEGF), Chinese hamster ovary (CHO) cells were transfected with dicistronic vectors designed to coexpress both heavy and light chains (Lucas et al., Nucleic Acid Res. 24:1774-79 (1996)). Plasmids were introduced into DP12 cells, a proprietary derivative of the CHO-K1 DUX B11 cell line developed by L. Chasin (Columbia University), via lipofection and selected for growth in GHT-free medium (Chisholm, V. High efficiency gene transfer in mammalian cells. In: Glover, DM, Hames, BD. DNA Cloning 4. Mammalian systems. Oxford Univ. Press, Oxford pp 1-41 (1996)). Approximately 20 unamplified clones were randomly chosen and reseeded into 96 well plates. Relative specific productivity of each colony was monitored using an ELISA to quantitate the full length human IgG accumulated in each well after 3 days and a fluorescent dye, Calcien AM, as a surrogate marker of viable cell number per well. Based on these data, several unamplified clones were chosen for further amplification in the presence of increasing concentrations of methotrexate. Individual clones surviving at 10, 50, and 100 nM methotrexate were chosen and transferred to 96 well plates for productivity screening. One clone, which reproducibly exhibited high specific productivity, was expanded in T-flasks and used to inoculate a spinner culture. After several passages, the suspension-adapted cells were used to inoculate production cultures in GHTcontaining, serum-free media supplemented with various hormones and protein hydrolysates. Harvested cell culture fluid containing rhuMAb VEGF was purified using protein A-Sepharose CL-4B. The purity after this step was ~99%. Subsequent purification to homogeneity was carried out using an ion exchange chromatography step. The endotoxin content of the final purified antibody was < 0.10 eu/mg.

F(ab) and *IgG Quantitation*: For quantitating F(ab) molecules, ELISA plates were coated with 2 μg/ml goat anti-human IgG Fab (Organon Teknika, Durham, NC) in 50 mM carbonate buffer, pH 9.6, at 4°C overnight and blocked with PBS-0.5% bovine serum albumin (blocking buffer) at room temperature for 1 h. Standards (0.78 - 50 ng/ml human F(ab)) were purchased from Chemicon (Temecula, CA). Serial dilutions of samples in PBS-0.5% bovine serum albumin-0.05% polysorbate 20 (assay buffer) were incubated on the plates for 2 h. Bound F(ab) was detected using horseradish peroxidase-labeled goat anti-human IgG F(ab) (Organon Teknika), followed by 3,3',5,5'-tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithersburg, MD) as the substrate. Plates were washed between steps. Absorbance was read at 450 nm on a

30

5

10

Vmax plate reader (Molecular Devices, Menlo Park, CA). The standard curve was fit using a four-parameter nonlinear regression curve-fitting program. Data points which fell in the range of the standard curve were used for calculating the F(ab) concentrations of samples. The concentration of full-length antibody was determined using goat anti-human IgG Fc (Cappel, Westchester, PA) for capture and horseradish peroxidase-labeled goat anti-human Fc (Cappel) for detection. Human IgG1 (Chemicon) was used as standard.

WEGF Binding Assay: For measuring the VEGF binding activity of F(ab)s, ELISA plates were coated with 2 μg/ml rabbit F(ab')₂ to human IgG Fc (Jackson ImmunoResearch, West Grove, PA) and blocked with blocking buffer (described above). Diluted conditioned medium containing 3 ng/ml of KDR-IgG (Park et al., J. Biol. Chem. 269:25646-25645 (1994)) in blocking buffer were incubated on the plate for 1 h. Standards (6.9 - 440 ng/ml chimeric F(ab)) and two-fold serial of samples were incubated with 2 nM biotinylated VEGF for 1 h in tubes. The solutions from the tubes were then transferred to the ELISA plates and incubated for 1 h. After washing, biotinylated VEGF bound to KDR was detected using horseradish peroxidase-labeled streptavidin (Zymed, South San Francisco, CA or Sigma, St. Louis, MO) followed by 3,3',5,5'-tetramethylbenzidine as the substrate. Titration curves were fit with a four-parameter nonlinear regression curve-fitting program (KaleidaGraph, Synergy Software, Reading PA). Concentrations of F(ab) variants corresponding to the midpoint absorbance of the titration curve of the standard were calculated and then divided by the concentration of the standard corresponding to the midpoint absorbance of the standard titration curve. Assays for full-length IgG were the same as for the F(ab)s except that the assay buffer contained 10% human serum.

BIAcore™ Biosensor Assay: VEGF binding of the humanized and chimeric F(ab)s were compared using a BIAcore™ biosensor (Karlsson et al. Methods: A Comparison to Methods in Enzymology 6:97-108 (1994)). Concentrations of F(ab)s were determined by quantitative amino acid analysis. VEGF was coupled to a CM-5 biosensor chip through primary amine groups according to manufacturer's instructions (Pharmacia). Off-rate kinetics were measured by saturating the chip with F(ab) (35 μl of 2 μM F(ab) at a flow rate of 20 μl/min) and then switching to buffer (PBS-0.05% polysorbate 20). Data points from 0 - 4500 sec were used for off-rate kinetic analysis. The dissociation rate constant (k_{off}) was obtained from the slope of the plot of ln(R0/R) versus time, where R0 is the signal at t=0 and R is the signal at each time point.

30

5

10

On-rate kinetics were measured using two-fold serial dilutions of F(ab) (0.0625 - 2 mM). The slope, K_s, was obtained from the plot of ln(-dR/dt) versus time for each F(ab) concentration using the BIAcoreTM kinetics evaluation software as described in the Pharmacia Biosensor manual. R is the signal at time t. Data between 80 and 168, 148, 128, 114, 102, and 92 sec were used for 0.0625, 0.125, 0.25, 0.5, 1, and 2 mM F(ab), respectively. The association rate constant (k_{on}) was obtained from the slope of the plot of K_s versus F(ab) concentration. At the end of each cycle, bound F(ab) was removed by injecting 5 µl of 50 mM HCl at a flow rate of 20 µl/min to regenerate the chip.

Endothelial Cell Growth Assay: Bovine adrenal cortex-derived capillary endothelial cells were cultured in the presence of low glucose Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10% calf serum, 2 mM glutamine, and antibiotics (growth medium), essentially as previously described (Leung et al. Science 246:1306-1309 (1989)). For mitogenic assays, endothelial cells were seeded at a density of 6 x 10³ cells per well, in 6-well plates in growth medium. Either muMAb VEGF A.4.6.1 or rhuMAb VEGF was then added at concentrations ranging between 1 and 5000 ng/ml. After 2-3 hr, purified E.coli-expressed rhVEGF165 was added to a final concentration of 3 ng/ml. For specificity control, each antibody was added to endothelial cells at the concentration of 5000 ng/ml, either alone or in the presence of 2 ng/ml bFGF. After five or six days, cells were dissociated by exposure to trypsin and counted in a Coulter counter (Coulter Electronics, Hialeah, FL). The variation from the mean did not exceed 10%. Data were analyzed by a four-parameter curve fitting program (KaleidaGraph).

In Vivo Tumor Studies: Human A673 rhabdomyosarcoma cells (ATCC; CRL 1598) were cultured as previously described in DMEM/F12 supplemented with 10% fetal bovine serum, 2 mM glutamine and antibiotics (Kim et al. Nature 362:841-844 (1993) and Borgström et al. Cancer Res. 56:4032-4039 (1996)). Female BALB/c nude mice, 6-10 weeks old, were injected subcutaneously with 2 x 10⁶ tumor cells in the dorsal area in a volume of 200 μl. Animals were then treated with muMAb VEGF A.4.6.1, rhuMAb VEGF or a control MAb directed against the gp120 protein (Kim et al. Nature 362:841-844 (1993)). Both anti-VEGF MAbs were administered at the doses of 0.5 and 5 mg/kg; the control MAb was given at the dose of 5 mg/kg. Each MAb was administered twice weekly intra peritoneally in a volume of 100 μl, starting 24 hr after tumor cell inoculation. Each group consisted of 10 mice. Tumor size was determined at weekly intervals. Four weeks

after tumor cell inoculation, animals were euthanized and the tumors were removed and weighed. Statistical analysis was performed by ANOVA.

RESULTS

5

10

The state of the s

Humanization: The consensus sequence for the human heavy chain subgroup III and the light chain subgroup k I were used as the framework for the humanization (Kabat *et al.*, *supra*) (Figs. 1A and 1B). This framework has been successfully used in the humanization of other murine antibodies (Werther *et al.*, *supra*; Carter *et al.*, *supra*; Presta *et al. J. Immunol.* 151:2623-2632 (1993); and Eigenbrot *et al. Proteins* 18:49-62 (1994)). CDR-H1 included residues H26-H35. The other CDRs were according to Kabat *et al.*, *supra*. All humanized variants were initially made and screened for binding as F(ab)s expressed in *E. coli.* Typical yields from 500 ml shake flasks were 0.1-0.4 mg F(ab).

The chimeric F(ab) was used as the standard in the binding assays. In the initial variant, F(ab)-1, the CDR residues were transferred from the murine antibody to the human framework and, based on the models of the murine and humanized F(ab)s, the residue at position H49 (Ala in human) was changed to the murine Gly. In addition, F(ab)s which consisted of the chimeric heavy chain/F(ab)-1 light chain (F(ab)-2) and F(ab)-1 heavy chain/chimeric light chain (F(ab)-3) were generated and tested for binding. F(ab)-1 exhibited a binding affinity greater than 1000-fold reduced from the chimeric F(ab) (Table 2). Comparing the binding affinities of F(ab)-2 and F(ab)-3 suggested that framework residues in the F(ab)-1 VH domain needed to be altered in order to increase binding.

25

30

Table 2: Binding of Humanized Anti-VEGF F(ab) Variants to VEGF^a

Variant	Template	Changes⁵	Purpose	EC50	(-(ab) F	(
				EC50 chimeric F(ab) ^c		ic
				Mean	S.D.	N
chim- F(ab)	Chimeric F(ab)			1.0		
F(ab)-1	Human FR		Straight CDR swap AlaH49 <u>Gly</u>	>1350		2
F(ab)-2			Chimera Light Chain F(ab)-1 Heavy Chain	>145		3
F(ab)-3			F(ab)-1 Light Chain Chimera Heavy Chain	2.6	0.1	2
F(ab)-4	F(ab)-1	ArgH71 <u>Leu</u> AsnH73 <u>Thr</u>	CDR-H2 conformation Framework	>295		3
F(ab)-5	F(ab)-4	LeuL46 <u>Val</u>	VL-VH interface	80.9	6.5	2
F(ab)-6	F(ab)-5	LeuH78Ala	CDR-H1 conformation	36.4	4.2	2
F(ab)-7	F(ab)-5	lleH69 <u>Phe</u>	CDR-H2 conformation	45.2	2.3	2
F(ab)-8	F(ab)-5	IleH69 <u>Phe</u> LeuH78 <u>Ala</u>	CDR-H2 conformation CDR-H1 conformation	9.6	0.9	4
F(ab)-9	F(ab)-8	GlyH49Ala	CDR-H2 conformation	>150		2
F(ab)-10	F(ab)-8	AsnH76 <u>Ser</u>	Framework	6.4	1.2	4
F(ab)-11	F(ab)-10	LysH75 <u>Ala</u>	Framework	3.3	0.4	2
F(ab)-12	F(ab)-10	ArgH94 <u>Lys</u>	CDR-H3 conformation	1.6	0.6	4

^aAnti-VEGF F(ab) variants were incubated with biotinylated VEGF and then transferred to ELISA plates coated with KDR-IgG (Park *et al.*, *supra*).

Haran All

15

5

^bMurine residues are underlined; residue numbers are according to Kabat *et al.*, *supra*. ^cMean and standard deviation are the average of the ratios calculated for each of the independent assays; the EC50 for chimeric F(ab) was 0.049 ± 0.013 mg/ml (1.0 nM).

10

Changing human residues H71 and H73 to their murine counterparts in F(ab)-4 improved binding by 4-fold (Table 2). Inspection of the models of the murine and humanized F(ab)s suggested that residue L46, buried at the VL-VH interface and interacting with CDR-H3 (Fig. 2), might also play a role either in determining the conformation of CDR-H3 and/or affecting the relationship of the VL and VH domains. When the murine Val was exchanged for the human Leu at L46 (F(ab)-5), the binding affinity increased by almost 4-fold (Table 2). Three other buried framework residues were evaluated based on the molecular models: H49, H69 and H78. Position H69 may affect the conformation of CDR-H2 while position H78 may affect the conformation of CDR-H1 (Figure 2). When each was individually changed from the human to murine counterpart, the binding improved by 2-fold in each case (F(ab)-6 and F(ab)-7, Table 2). When both were simultaneously changed, the improvement in binding was 8-fold (F(ab)-8, Table 2). Residue H49 was originally included as the murine Gly; when changed to the human consensus counterpart Ala the binding was reduced by 15-fold (F(ab)-9, Table 2).

In F(ab)-10 and F(ab)-11 two residues in framework loop 3, FR-3, were changed to their murine counterparts: AsnH76 to murine Ser (F(ab)-10) and LysH75 to murine Ala (F(ab)-11). Both effected a relatively small improvement in binding (Table 2). Finally, at position H94 human and murine sequences most often have an Arg (Kabat *et al.*, *supra*). In F(ab)-12, this Arg was replaced by the rare Lys found in the murine antibody (Fig.1A) and this resulted in binding which was less than 2-fold from the chimeric F(ab) (Table 2). F(ab)-12 was also compared to the chimeric F(ab) using the BIAcoreTM system (Pharmacia). Using this technique the K_d of the humanized F(ab)-12 was 2-fold weaker than that of the chimeric F(ab) due to both a slower k_{on} and faster k_{off} (Table 3).

Table 3: Binding of Anti-VEGF F(ab) Variants to VEGF Using the BIAcore™ System^a

Variant	Amount of (Fab) bound (RU)	k _{off} (s ⁻¹⁾	k _{on} (M ⁻¹ s ⁻¹)	K _d (nM)
chim- F(ab)⁵	4250	5.9x10 ⁻⁵	6.5x10⁴	0.91
F(ab)-12	3740	6.3x10 ⁻⁵	3.5x10⁴	1.8

^a The amount of F(ab) bound, in resonance units (RU), was measured using a BIAcore[™] system when 2 μg F(ab) was injected onto a chip containing 2480 RU immobilized VEGF. Off-rate kinetics (k_{off}) were measured by saturating the chip with F(ab) and then monitoring dissociation after switching to buffer. On-rate kinetics (k_{on}) were measured using two-fold serial dilutions of F(ab). K_{d} , the equilibrium dissociation constant, was calculated as k_{off}/k_{on} . b chim-F(ab) is a chimeric F(ab) with murine VL and VH domains fused to human CL and CH1 heavy domains.

10

5

Full length mAbs were constructed by fusing the VL and VH domains of the chimeric F(ab) and variant F(ab)-12 to the constant domains of human k light chain and human lgG1 heavy chain. The full length 12-lgG1 (F(ab)-12 fused to human lgG1) exhibited binding which was 1.7-fold weaker than the chimeric lgG1 (Table 4). Both 12-lgG1 and the chimeric lgG1 bound slightly less well than the original murine mAb A4.6.1 (Table 4).

Table 4: Binding of Anti-VEGF IgG Variants to VEGF

	lgG1/chlgG1 ^b					
Variant	Mean	S.D.	N			
chlgG1	1.0		2			
murlgG1°	0.759	0.001	2			
12-lgG1⁴	1.71	0.03	2			

^a Anti-VEGF IgG variants were incubated with biotinylated VEGF and then transferred to ELISA plates coated with KDR-IgG (Park et al., (1994), supra).

30

Biological Studies: rhuMAb VEGF and muMAb VEGF A.4.6.1, were compared for their ability to inhibit bovine capillary endothelial cell proliferation in response to a near maximally effective concentration of VEGF (3 ng/ml). As illustrated in Figure 3, the two MAbs were essentially equivalent, both in potency and efficacy. The ED50 values were respectively 50 ± 5 ng/ml and 48 ± 8 ng/ml (~0.3 nM). In both cases 90% inhibition was achieved at the concentration of 500 ng/ml (~3 nM). Neither muMAb VEGF A.4.6.1 nor rhuMAb VEGF had any

35

bchlgG1 is chimeric lgG1 with murine VL and VH domains fused to human CL and lgG1 heavy chains; the EC50 for chlgG1 was 0.113 ± 0.013 µg/ml (0.75 nM).

^cmurlgG1 is muMAbVEGF A461 purified from ascites.

d12-IgG1 is F(ab)-12 VL and VH domains fused to human CL and IgG1 heavy chains.

effect on basal or bFGF-stimulated proliferation of capillary endothelial cells, confirming that the inhibition is specific for VEGF.

To determine whether such equivalency applies also to an *in vivo* system, the two antibodies were compared for their ability to suppress the growth of human A673 rhabdomyosarcoma cells in nude mice. Previous studies have shown that muMAb VEGF A.4.6.1 has a dramatic inhibitory effect in this tumor model (Kim *et al. Nature* 362:841-844 (1993) and Borgström *et al. Cancer Res* 56:4032-4039 (1996)). As shown in Figure 4, at both doses tested (0.5 and 5 mg/kg), the two antibodies markedly suppressed tumor growth as assessed by tumor weight measurements four weeks after cell inoculation. The decreases in tumor weight compared to the control group were respectively 85% and 93% at each dose in the animals treated with muMAb VEGF A.4.6.1. versus 90% and 95% in those treated with rhuMAb VEGF. Similar results were obtained with the breast carcinoma cell line MDA-MB 435.

5

10

20

25

30

EXAMPLE 2

In this example, the murine anti-VEGF antibody A4.6.1 discussed above was humanized by randomizing a small set of framework residues and by monovalent display of the resultant library of antibody molecules on the surface of filamentous phage in order to identify high affinity framework sequences via affinity-based selection.

MATERIALS AND METHODS

Construction of Anti-VEGF Phagemid Vector, pMB4-19: The murine anti-VEGF mAb A4.6.1 is discussed above in Example 1. The first Fab variant of humanized A4.6.1, hu2.0, was constructed by site-directed mutagenesis using a deoxyuridine-containing template of plasmid pAK2 (Carter et al. Proc. Natl. Acad. Sci. U.S.A. 89:4285-4289 (1992)) which codes for a human V_LKI-CK₁ light chain and human V_HIII-C_H1γ₁ heavy chain Fd fragment. The transplanted A4.6.1 CDR sequences were chosen according to the sequence definition of Kabat et al., supra, except for CDR-H1 which included residues 26-35. The Fab encoding sequence was subcloned into the phagemid vector phGHamg3 (Bass et al. Proteins 8:309-314 (1990) and Lowman et al. Biochemistry 30:10832-10838 (1991)). This construct, pMB4-19, encodes the initial humanized A4.6.1 Fab, hu2.0, with the C-terminus of the heavy chain fused precisely to the carboxyl portion

30

5

10

of the M13 gene III coat protein. pMB4-19 is similar in construction to pDH188, a previously described plasmid for monovalent display of Fab fragments (Garrard et al. Biotechnology 9:1373-1377 (1991)). Notable differences between pMB4-19 and pDH188 include a shorter M13 gene III segment (codons 249-406) and use of an amber stop codon immediately following the antibody heavy chain Fd fragment. This permits expression of both secreted heavy chain or heavy chain-gene III fusions in *supE* suppressor strains of *E. coli*.

Expression and Purification of Humanized A4.6.1 Fab Fragment: E. coli strain 34B8, a nonsuppressor, was transformed with phagemid pMB4-19, or variants thereof. Single colonies were grown overnight at 37°C in 5 mL 2YT containing 50 μg/mL carbenicillin. These cultures were diluted into 200 mL AP5 medium (Chang et al. Gene 55:189-196 (1987)) containing 20 μg/mL carbenicillin and incubated for 26 hr at 30°C. The cells were pelleted at 4000 x g and frozen at -20°C for at least 2 h. Cell pellets were then resuspended in 5 mL of 10 mM Tris-HCl (pH 7.6) containing 1 mM EDTA, shaken at 4°C for 90 min and centrifuged at 10,000 x g for 15 min. The supernatant was applied to a 1 mL streptococcal protein G-sepharose column (Pharmacia) and washed with 10 mL of 10 mM MES (pH 5.5). The bound Fab fragment was eluted with 2.5 mL 100 mM acetic acid and immediately neutralized with 0.75 mL 1M Tris-HCl, pH 8.0. Fab preparations were buffer-exchanged into PBS and concentrated using Centricon-30 concentrators (Amicon). Typical yields of Fab were ~1 mg/L culture, post-protein G purification. Purified Fab samples were characterized by electrospray mass spectrometry, and concentrations were determined by amino acid analysis.

Construction of the Anti-VEGF Fab Phagemid Library: The humanized A4.6.1 phagemid library was constructed by site-directed mutagenesis according to the method of Kunkel et al. Methods Enzymol. 204:125-139 (1991)). A derivative of pMB4-19 containing TAA stop triplets at V_H codons 24, 37, 67 and 93 was prepared for use as the mutagenesis template (all sequence numbering according to Kabat et al., supra). This modification was to prevent subsequent background contamination by wild type sequences. The codons targeted for randomization were 4 and 71 (light chain) and 24, 37, 67, 69, 71, 73, 75, 76, 78, 93 and 94 (heavy chain).

In order to randomize heavy chain codons 67, 69, 71, 73, 75, 76, 78, 93 and 94 with a single mutagenic oligonucleotide, two 126-mer oligonucleotides were first preassembled from 60

and 66-mer fragments by template-assisted enzymatic ligation. Specifically, 1.5 nmol of 5' phosphorylated oligonucleotide 503-1 (5'-GAT TTC AAA CGT CGT NYT ACT WTT TCT AGA GAC AAC TCC AAA AAC ACA BYT TAC CTG CAG ATG AAC-3' (SEQ ID NO:22)) or 503-2 (5'-GAT TTC AAA CGT CGT NYT ACT WTT TCT TTA GAC ACC TCC GCA AGC ACA BYT TAC CTG CAG ATG AAC-3' (SEQ ID NO:23)) were combined with 1.5 nmol of 503-3 (5'-AGC CTG CGC GCT GAG GAC ACT GCC GTC TAT TAC TGT DYA ARG TAC CCC CAC TAT TAT GGG-3' (SEQ ID NO:24)) (randomized codons underlined; N=A/G/T/C; W=A/T; B=G/T/C; D=G/A/T; R=A/G; Y=C/T). Then, 1.5 nmol of template oligonucleotide (5'-CTC AGC GCG CAG GCT GTT CAT CTG CAG GTA-3' (SEQ ID NO:25)), with complementary sequence to the 5' ends of 503-1/2 and the 3' end of 503-3, was added to hybridize to each end of the ligation junction. Taq ligase (thermostable ligase from New England Biolabs) and buffer were added, and the reaction mixture was subjected to 40 rounds of thermal cycling, (95°C 1.25 min; 50°C for 5 min) so as to cycle the template oligonucleotide between ligated and unligated junctions. The product 126-mer oligonucleotides were purified on a 6% urea/TBE polyacrylamide gel and extracted from the polyacrylamide in buffer. The two 126-mer products were combined in equal ratio, ethanol precipitated and finally solubilized in 10mM Tris-HCl, 1mM EDTA. The mixed 126-mer oligonucleotide product was labeled 504-01.

5

10

Harry many

.

20

25

30

Randomization of select framework codons (V_L 4, 71; V_H 24, 37, 67, 69, 71, 73, 75, 76, 93, 94) was effected in two steps. Firstly, V_L randomization was achieved by preparing three additional derivatives of the modified pMB4-19 template. Framework codons 4 and 71 in the light chain were replaced individually or pairwise using the two mutagenic oligonucleotides 5'-GCT GAT ATC CAG TTG ACC CAG TCC CCG-3' (SEQ ID NO:26) 5'-and TCT GGG ACG GAT TAC ACT CTG ACC ATC-3' (SEQ ID NO:27). Deoxyuridine-containing template was prepared from each of these new derivatives. Together with the original template, these four constructs coded for each of the four possible light chain framework sequence combinations (Table 5).

Oligonucleotides 504-1, a mixture of two 126-mer oligonucleotides (see above), and 5'-CGT TTG TCC TGT GCA RYT TCT GGC TAT ACC TTC ACC AAC TAT GGT ATG AAC TGG RTC CGT CAG GCC CCG GGT AAG-3' (SEQ ID NO:28) were used to randomize heavy chain framework codons using each of the four templates just described. The four libraries were electroporated into *E. coli* XL-1 Blue cells (Stratagene) and combined. The total number of

independent transformants was estimated at >1.2 x 10⁸, approximately 1,500-fold greater than the maximum number of DNA sequences in the library.

A variety of systems have been developed for the functional display of antibody fragments on the surface of filamentous phage. Winter *et al.*, *Ann. Rev. Immunol.* 12,433 (1994). These include the display of Fab or single chain Fv (scFv) fragments as fusions to either the gene III or gene VIII coat proteins of M13 bacteriophage. The system selected herein is similar to that described by Garrard *et al.*, *Biotechn*, 9,1373 (1991) in which a Fab fragment is monovalently displayed as a gene III fusion (Figure 7). This system has two notable features. In particular, unlike scFvs, Fab fragments have no tendency to form dimeric species, the presence of which can prevent selection of the tightest binders due to avidity effects. Additionally the monovalency of the displayed protein eliminates a second potential source of avidity effects that would otherwise result from the presence of multiple copies of a protein on each phagemid particle. Bass and Wells, *Proteins* 8:309 (1990) and Lowman *et al.*, *Biochemistry* 30:10832 (1991).

5

10

1.7

20

25

30

Phagemid particles displaying the humanized A4.6.1 Fab fragments were propagated in *E. coli* XL-1 Blue cells. Briefly, cells harboring the randomized pMB4-19 construct were grown overnight at 37°C in 25 mL 2YT medium containing 50μg/mL carbenicillin and approximately 10¹⁰ M13KO7 helper phage (Vieira & Messing *Methods Enzymol.* 153:3-11 (1987)). Phagemid stocks were purified from culture supernatants by precipitation with a saline polyethylene glycol solution, and resuspended in 100 μL PBS (~10¹⁴ phagemid/mL)

Selection of Humanized A4.6.1 Fab Variants: Purified VEGF₁₂₁ (100 μL at 10μg/mL in PBS) was coated onto a microtiter plate well overnight at 4°C. The coating solution was discarded and this well, in addition to an uncoated well, were blocked with 6% skim milk for 1 h and washed with PBS containing 0.05% TWEEN 20™ (detergent). Then, 10 μL of phagemid stock, diluted to 100 μL with 20 mM Tris (pH 7.5) containing 0.1% BSA and 0.05%TWEEN 20™, was added to each well. After 2 hours the wells were washed and the bound phage eluted with 100 μL of 0.1 M glycine (pH 2.0), and neutralized with 25 μL of 1M Tris pH 8.0. An aliquot of this was used to titer the number of phage eluted. The remaining phage eluted from the VEGF-coated well were propagated for use in the next selection cycle. A total of 8 rounds of selection was performed after which time 20 individual clones were selected and sequenced (Sanger *et al. Proc. Natl. Acad. Sci. U.S.A.* 74:5463-5467 (1977)).

10

Determination of VEGF Binding Affinities: Association (k_{on}) and dissociation (k_{off}) rate constants for binding of humanized A4.6.1 Fab variants to VEGF₁₂₁ were measured by surface plasmon resonance (Karlsson *et al. J. Immun. Methods* 145:229-240 (1991)) on a Pharmacia BIAcore instrument. VEGF₁₂₁ was covalently immobilized on the biosensor chip via primary amino groups. Binding of humanized A4.6.1 Fab variants was measured by flowing solutions of Fab in PBS/0.05% TWEEN 20TM over the chip at a flow rate of 20 μL/min. Following each binding measurement, residual Fab was stripped from the immobilized ligand by washing with 5 μL of 50 mM aqueous HCl at 3 μL/min. Binding profiles were analyzed by nonlinear regression using a simple monovalent binding model (BIAevaluation software v2.0; Pharmacia).

RESULTS

Construction of Humanized A4.6.1: An initial humanized A4.6.1 Fab fragment was constructed (hu2.0, Figs. 5A and 5B), in which the CDRs from A4.6.1 were grafted onto a human $V_L \kappa I - V_H III$ framework. All other residues in hu2.0 were maintained as the human sequence. Binding of this variant to VEGF was so weak as to be undetectable. Based on the relative affinity of other weakly-binding humanized A4.6.1 variants, the K_D for binding of hu2.0 was estimated at >7 μ M. This contrasts with an affinity of 1.6 nM for a chimeric Fab construct consisting of the intact V_L and V_H domains from murine A4.6.1 and human constant domains. Thus binding of hu2.0 to VEGF was at least 4000-fold reduced relative to the chimera.

Design of Antibody Library: The group of framework changes to the human framework sequence herein is shown in Table 5 and Fig. 6.

Table 5: Key Framework Residues Important for Antigen Binding and Targeted for Randomization

	amework Human Vĸ _L I, residue V _H III consensus residue		Murine A4.6.1 residue	Randomization	
V _L :	4	Met	Met	Met, Leu	
	71	Phe	Tyr	Phe, Tyr	
V _H :	24	Ala	Ala	Ala, Val, Thr	
	37	Val	Val	Val, Ile	

30

25

30

5

67	Phe	Phe	Phe, Val, Thr, Leu, Ile, Ala
69	lle	Phe	lle, Phe
71	Arg	Leu	Arg ^b , Leu ^b
73	Asp	Thr	Asp⁵, Thr⁵
75	Lys	Ala	Lys ^b , Ala ^b
76	Asn	Ser	Asn ^b , Ser ^b
78	Leu	Ala	Leu, Ala, Val, Phe
93	Ala	Ala	Ala, Val, Leu, Ser, Thr
94	Arg	Lys	Arg, Lys

^aAmino acid diversity in phagemid library

A concern in designing the humanized A4.6.1 phagemid library was that residues targeted for randomization were widely distributed across the V_L and V_H sequences. Limitations in the length of synthetic oligonucleotides requires that simultaneous randomization of each of these framework positions can only be achieved through the use of multiple oligonucleotides. However, as the total number of oligonucleotides increases, the efficiency of mutagenesis decreases (*i.e.* the proportion of mutants obtained which incorporate sequence derived from all of the mutagenic oligonucleotides). To circumvent this problem, two features were incorporated into the library construction. The first was to prepare four different mutagenesis templates coding for each of the possible V_L framework combinations. This was simple to do given the limited diversity of the light chain framework (only 4 different sequences), but was beneficial in that it eliminated the need for two oligonucleotides from the mutagenesis strategy. Secondly, two 126-base oligonucleotides were preassembled from smaller synthetic fragments. This made possible randomization of V_H codons 67, 69, 71, 73, 75, 76, 93 and 94 with a single long oligonucleotide, rather than two smaller ones. The final randomization mutagenesis strategy therefore employed only two oligonucleotides simultaneously onto four different templates.

Selection of Tight Binding Humanized A4.6.1 Fab's: Variants from the humanized A4.6.1 Fab phagemid library were selected based on binding to VEGF. Enrichment of functional

 $^{^{\}rm b}V_{\rm H}71$, 73, 75, 76 randomized to yield the all-murine (L71/T73/A75/S76) or all-human (R71/D73/K75/N76) $V_{\rm H}II$ tetrad

phagemid, as measured by comparing titers for phage eluted from a VEGF-coated versus uncoated microtiter plate well, increased up to the seventh round of affinity panning. After one additional round of sorting, 20 clones were sequenced to identify preferred framework residues selected at each position randomized. These results, summarized in Table 6, revealed strong consensus amongst the clones selected. Ten out of the twenty clones had the identical DNA sequence, designated hu2.10. Of the thirteen framework positions randomized, eight substitutions were selected in hu2.10 (V_L 71; V_H 37, 71, 73, 75, 76, 78 and 94). Interestingly, residues V_H 37 (IIe) and 78 (Val) were selected neither as the human V III or murine A4.6.1 sequence. This result suggests that some framework positions may benefit from extending the diversity beyond the target human and parent murine framework sequences.

Table 6: Sequences Selected from the Humanized A4.6.1 Phagemid Fab Library

Variant	Re	sidue	subst	itutior	าร								
	V _L		V _H										
	4	71	24	37	67	69	71	73	75	76	78	93	94
murine A4.6.1	М	Y	А	٧	F	F	L	Т	Α	S	Α	Α	К
hu2.0 (CDR- graft)	М	Ē	А	٧	F	<u>Į</u>	R	N	K	N	<u>L</u>	Α	R
Phage-sele	ected	cione	es:										
hu2.1(2)	-	Υ	-	ı	-	-	-	-	-	-	٧	-	К
hu2.2(2)	L	Y	-	1	-	-	-	-	-	-	٧	-	к
hu2.6(1)	L	-	-	1	Т	-	L	Т	Α	s	٧	-	К
hu2.7(1)	L	-	-	1	-	-	-	-	-	_	٧	-	К
hu2.10(10)	_	Y	-	1	-	-	L	Т	Α	s	V	-	К

Differences between hu2.0 and murine A4.6.1 antibodies are underlined. The number of identical clones identifies for each phage-selected sequence is indicated in parentheses. Dashes in the sequences of phage-selected clones indicate selection of the human $V_L KI - V_H III$ framework sequence (i.e. as in hu2.0).

There were four other unique amino acid sequences among the remaining ten clones analyzed: hu2.1, hu2.2, hu2.6 and hu2.7. All of these clones, in addition to hu2.10, contained identical framework substitutions at positions V_H 37 (IIe), 78 (Val) and 94 (Lys), but retained the human V_H III consensus sequence at positions 24 and 93. Four clones had lost the light chain coding sequence and did not bind VEGF when tested in a phage ELISA assay (Cunningham *et al. EMBO J.* 13:2508-251 (1994)). Such artifacts can often be minimized by reducing the number of sorting cycles or by propagating libraries on solid media.

Expression and Binding Affinity of Humanized A4.6.1 Variants: Phage-selected variants hu2.1, hu2.2, hu2.6, hu2.7 and hu2.10 were expressed in $E.\ coli$ using shake flasks and Fab fragments were purified from periplasmic extracts by protein G affinity chromatography. Recovered yields of Fab for these five clones ranged from 0.2 (hu2.6) to 1.7 mg/L (hu2.1). The affinity of each of these variants for antigen (VEGF) was measured by surface plasmon resonance on a BIAcore instrument (Table 7). Analysis of this binding data revealed that the consensus clone hu2.10 possessed the highest affinity for VEGF out of the five variants tested. Thus the Fab phagemid library was selectively enriched for the tightest binding clone. The calculated K_D for hu2.10 was 55 nM, at least 125-fold tighter than for hu2.0 which contains no framework changes ($K_D > 7 \mu M$). The other four selected variants all exhibited weaker binding to VEGF, ranging down to a K_D of 360 nM for the weakest (hu2.7). Interestingly, the K_D for hu2.6, 67 nM, was only marginally weaker than that of hu2.10 and yet only one copy of this clone was found among 20 clones sequenced. This may have due to a lower level of expression and display, as was the case when expressing the soluble Fab of this variant. However, despite the lower expression rate, this variant is useful as a humanized antibody.

Table 7: VEGF Binding Affinity of Humanized A4.6.1 Fab Variants

Variant	k _{on} M⁻¹s-¹/10⁴	k ₀ _{ff} 10⁴s⁻¹	K _D nM	<u>K_D(A4.6.1)</u> Κ _D (mut)
A4.6.1 chimera	5.4	0.85	1.6	>4000
hu2.0	ND	ND	>7000**	
Phage selected o	lones:			
hu2.1	0.70	18	260	170

hu2.2	0.47	16	340	
hu2.6	0.67	4.5	67	
hu2.7	0.67	24	360	
hu2.10	0.63	3.5	55	
*hu2.10V	2.0	1.8	9.3	
Estimated errors i	0 with mutation V _L L in the Biacore bindir easure; estimate of l	ng measurements a	are +/-25%.	
Additional	Improvement of H	umanized Variant	hu2.1: Despite the	ne larg

10

1.4

. £

25

30

20

210

40

230

35

5.8

ge improvement in antigen affinity over the initial humanized variant, binding of hu2.10 to VEGF was still 35-fold weaker than a chimeric Fab fragment containing the murine A4.6.1 $V_{\scriptscriptstyle L}$ and $V_{\scriptscriptstyle H}$ domains. This considerable difference suggested that further optimization of the humanized framework might be possible through additional mutations. Of the Vernier residues identified by Foote & Winter J. Mol. Biol. 224:487-499 (1992), only residues V_L 46, V_H 2 and V_H 48 differed in the A4.6.1 versus human $V_L \kappa I - V_H III$ framework (Figs. 5A and 5B) but were not randomized in our phagemid library. A molecular model of the humanized A4.6.1 Fv fragment showed that V_L 46 sits at the V_L - V_H interface and could influence the conformation of CDR-H3. Furthermore, this amino acid is almost always leucine in most V, k frameworks (Kabat et al., supra), but is valine in A4.6.1. Accordingly, a Leu -> Val substitution was made at this position in the background of hu2.10. Analysis of binding kinetics for this new variant, hu2.10V, indicated a further 6-fold improvement in the K_D for VEGF binding, demonstrating the importance of valine at position V_L 46 in antibody A4.6.1. The ${\rm K_D}$ for hu2.10V (9.3 nM) was thus within 6-fold that of the chimera. In contrast to ${\rm V_L}$ 46, no improvement in the binding affinity of hu2.10 was observed for replacement of either $V_{\rm H}$ 2 or $V_{\rm H}$ 48 with the corresponding residue from murine A4.6.1.

EXAMPLE 3

In this example, CDR randomization, affinity maturation by monovalent Fab phage display, and cumulative combination of mutations were used to enhance the affinity of a humanized anti-VEGF antibody.

5

Construction of Humanized Antibody p Y0101: Phage-displayed antibody vector phMB4-19-1.6 (see Figs. 8A-E) was used as a parent. In this construct, anti-VEGF is expressed as a Fab fragment with its heavy chain fused to the N-terminus of the truncated g3p. Both the light and heavy chains are under the control of phoA promoter with an upstream stll signal-sequence for secretion into the periplasm. Point mutations outside the CDR regions were made by site-directed mutagenesis to improve affinity for VEGF with oligonucleotides HL-242, HL-243, HL-245, HL-246, HL-254, HL-256, and HL-257 as shown in Table 8 below:

Table 8: Oligos for Directed Mutations

Oligo Number	Region	Substitution/ Comments	Sequence
HL-242	VL	M4L	5'-GATATCCAGTTGACCCAGTCCCCG-3' (SEQ ID NO:29)
HL-243	VL	L46V	5'-GCTCCGAAAGTACTGATTTAC-3' (SEQ ID NO:30)
HL-245	VH	CDR-7	5'- CGTCGTTTCACTTTTTCTGCAGACACCT CCAGCAACACAGTATACCTGCAGATG-3' (SEQ ID NO:31)
HL-246	VH	R98K	5'-CTATTACTGTGCAAAGTACCCCCAC-3' (SEQ ID NO:32)
HL-254	VL	Y71F	5'-GGGACGGATTTCACTCTGACCATC-3' (SEQ ID NO:33)
HL-256	VH	137V	5'- GGTATGAACTGGGTCCGTCAGGCCCC-3' (SEQ ID NO:34)
HL-257	VH	CDR-7 A72L S76K N77S	5'- CGTCGTTTCACTTTTTCTTTAGACACCT CCAAAAGCACAGCATACCTGCAGATGAA C-3' (SEQ ID NO:35)

The resulting variant was termed Y0101 (Figs. 9A and 9B).

Construction of the First Generation of Antibody-Phage Libraries: To prevent contamination by wild-type sequence, templates with the TAA stop codon at the targeted sites for randomization were prepared and used for constructing libraries by site-directed mutagenesis

10

with oligonucleotides using the degenerate NNS codon (where N is an equal mixture of A, G, C, and T while S is an equal mixture of G and C) for saturation mutagenesis. VL1 and VH3 were chosen as potential candidates for affinity enhancement (Figs. 9A and B). Within the CDRs, two libraries were constructed from the pY0101 template. VL1 was mutated using stop-template oligonucleotides HL-248 and HL-249 (Table 9) and library oligonucleotides HL-258 and HL-259 (Table 10). Similarly, three libraries were constructed for VH3 using stop template oligonucleotides HL-250, HL-251, and HL-252 (Table 9), and library oligonucleotides HL-260, HL-261, and HL-262 (Table 10). Library construction is summarized in Tables 9 and 10 below.

Table 9: Template Oligos for Mutagenesis

Oligo Number	Region Comments	Sequence
HL-248	VL1	5'-GGGTCACCATCACCTGCTAAGCATAATAATAATAAAGCAACT ATTTAAACTGG-3' (SEQ ID NO:36)
HL-249	VL1	5'-GCGCAAGTCAGGATATTTAATAATAATAATAATGGTATCAAC AGAAACCAGG-3' (SEQ ID NO:37)
HL-250	HL-250 VH3 5'-GTCTATTACTGTGCAAAGTAATAACACTAATAAGGGAG CCACTGG-3' (SEQ ID NO:38)	
HL-251	VH3	5'-GGTACCCCACTATTATTAATAATAATAATGGTATTTCGACG TCTGGGG-3' (SEQ ID NO:39)
HL-252	VH3	5'-CACTATTATGGGAGCAGCCACTAATAATAATAAGTCTGGGT CAAGGAACCCTG-3' (SEQ ID NO:40)
HL-263	VH1	5'-TCCTGTGCAGCTTCTGGCTAATAATTCTAATAATAAGGTATG AACTGGGTCCG-3' (SEQ ID NO:41)
HL-264	VH2	5'-GAATGGGTTGGATGGATTAACTAATAATAAGGTTAACCGAC CTATGCTGCGG-3' (SEQ ID NO:42)
YC-80	VH3	5'-CTGTGCAAAGTACCCGTAATATTAATAATAATAACACTGGTA TTTCGAC-3' (SEQ ID NO:43)
YC-100	CDR7	5'-CGTTTCACTTTTTCTTAAGACTAATCCAAATAAACAGCATAC CTGCAG-3' (SEQ ID NO:44)
YC-102	VH2	5'-GAATGGGTTGGATGGATTTAATAATAATAAGGTGAACCGAC CTATG-3' (SEQ ID NO:45)

20

25

Table 10: Random Oligos for Library Construction

Oligo Number	Region Comment	Sequence
HL-258	VL1	5'-GGGTCACCATCACCTGCNNSGCANNSNNSNNSNNSAGC AACTATTTAAACTGG-3' (SEQ ID NO:46)
HL-259	VL1	5'-GCGCAAGTCAGGATATTNNSNNSNNSNNSNNSTGGTATCAACA GAAACCAGG-3' (SEQ ID NO:47)
HL-260	VH3	5'-GTCTATTACTGTGCAAAGNNSNNSCACNNSNNSGGGAGCAGC CACTGG-3' (SEQ ID NO:48)
HL-261	VH3	5'-GGTACCCCACTATTATNNSNNSNNSNNSTGGTATTTCGACGT CTGGGG-3' (SEQ ID NO:49)
HL-262	VH3	5'-CACTATTATGGGAGCAGCCACNNSNNSNNSNNSGTCTGGGGT CAAGGAACCCTG-3' (SEQ ID NO:50)
HL-265	VH1	5'-TCCTGTGCAGCTTCTGGCNNSNNSTTCNNSNNSNNSGGTATGA ACTGGGTCCG-3' (SEQ ID NO:51)
HL-266	VH2	5'-GAATGGGTTGGATGGATTAACNNSNNSNNSGGTNNSCCGACC TATGCTGCGG-3' (SEQ ID NO:52)
YC-81	VH3	5'-CTGTGCAAAGTACCCGNNSTATNNSNNSNNSNNSCACTGGTAT TTCGAC-3' (SEQ ID NO:53)
YC-101	CDR7	5'-CGTTTCACTTTTTCTNNSGACNNSTCCAAANNSACAGCATACCT GCAG-3' (SEQ ID NO:54)
YC-103	VH2	5'-GAATGGGTTGGATGGATTNNSNNSNNSNNSGGTGAACCGACC TATG-3' (SEQ ID NO:55)

The products of random mutagenesis reactions were electroporated into XL1-Blue *E.coli* cells (Stratagene) and amplified by growing 15-16 h with M13KO7 helper phage. The complexity of each library, ranging from 2×10^7 to 1.5×10^8 , was estimated based upon plating of the initial transformation onto carbenicillin plates.

Initial Affinity Selections: For each round of selection, approximately 10⁹-10¹⁰ phage were screened for binding to plates (Nunc Maxisorp 96-well) coated with 2 μg/mL VEGF (recombinant; residue 9-109 version) in 50 mM carbonate buffer, pH 9.6 and blocked with 5% instant milk in 50 mM carbonate buffer, pH 9.6. After 1-2 hour binding at room temperature, in the presence of 0.5% bovine serum albumin and 0.05% TWEEN 20™ in PBS, the phage solution was removed, and the plate was washed ten times with PBS/TWEEN™ (0.05% TWEEN 20™

30

5

10

in PBS buffer). Typically, to select for enhanced affinity variants with slower dissociation rates, the plates were incubated with PBS/TWEEN™ buffer for a period of time which lengthened progressively for each round of selection (from 0 minute for the first round, to 3 h for the ninth round of selection). After the PBS/TWEEN™ buffer was removed, the remained phages were eluted with 0.1 M HCl and immediately neutralized with 1/3 volume of 1 M Tris, pH 8.0. The eluted phages were propagated by infecting XL1-Blue *E.coli* cells (Stratagene) for the next selection cycle.

Sequencing data revealed that both VL1 libraries, even after the eighth/ninth round of sorting, remained diverse, tolerating various type of residues at the sites of randomization. In contrast, the VH3 libraries retained only wild type residues or had very conservative substitutions. This suggested that the VL1 was more exposed to solvent and lay outside the binding interface. In contrast, VH3 did not show dramatically different sidechain substitutions, and therefore might be more intimately involved in antigen binding.

Phage-ELISA Assay of Binding Affinities: From each of these libraries, representative clones (those represented by abundant sequences) were assayed for their affinities relative to that of parent clone pY0101 in a phage-ELISA assay. In such an assay, phages were first serially diluted to determine a fractional saturation titer which was then held constant and used to incubate with varying concentrations of VEGF (starting at 200 nM to 0 nM) in solution. The mixture was then transferred onto plate precoated with VEGF (2 μg/mL) and blocked with 5% instant milk, and allowed to equilibrate for 1 hour at room temperature. Thereafter, the phage solution was removed and the remaining bound phages were detected with a solution of rabbit anti-phage antibody mixed with goat anti-rabbit conjugate of horse radish peroxidase. After an hour incubation at room temperature, the plate was developed with a chromogenic substrate, *o*-phenylenediamine (Sigma). The reaction was stopped with addition of ½ volume of 2.5 M H₂SO₄. Optical density at 492nm was measured on a spectrophotometric plate reader.

Although all of the selected clones from these five libraries showed either weaker or similar affinities than that of wild type pY0101 in phage-ELISA assay, one particular variant (pY0192) from library HL-258 displayed an apparent advantage (about 10 fold) in the level of expression or phage display relative to pY0101. This clone contained mutations S24R, S26N, Q27E, D28Q, and I29L in the VL region (Fig. 9A). In addition, this variant was found to have a spurious

mutation, M34I, in VH. This variant showed no significant difference in binding affinity to VEGF as compared with the pY0101 variant. To improve the level of Fab-display on phage, and the signal-to-noise ratio for phage-ELISA assays, the corresponding substitutions in pY0192 at VL1 were incorporated into the template background for constructing both CDR Ala-mutants and the second generation of anti-VEGF libraries.

5

10

*. W K...

25

30

15

Ala-Scanning the CDRs of Anti-VEGF: To determine the energetics contributed by each of the amino acids in the CDR regions and thus better select target residues for randomization, the CDR regions were screened by substituting alanine for each residue. Each Ala mutant was constructed using site-directed mutagenesis with a synthetic oligonucleotide encoding for the specific alanine substitution. Where Ala was the wild-type residue, Ser was substituted to test the effect of a sidechain substitution. Phage clones having a single Ala mutation were purified and assayed in phage-ELISA as described above. Results of the Ala-scan demonstrated that Ala-substitution at various positions can have an effect, ranging from 2 to > 150 fold reductions, on antigen binding affinity compared to pY0192. In addition, it confirmed a previous observation that VH3, but not VL1, was involved in antigen binding. Results of the CDR Ala-scan are summarized in Table 11 below.

Table 11: Relative VEGF Affinities of Ala-Scan Fab Variants

Residue	IC50 (mut)	Residue	IC50 (mut)
VL	IC50 (wt)	VH	IC50 (wt)
R24A	1	G26A	2
A25S	1	Y27A	34
N26A	1	T28A	1
E27A	1	F29A	16
Q28A	1	T30A	1
L29A	1	N31A	>150
S30A	2	Y32A	>150
N31A	2	G33A	6
Y32A	2	134A	6
L33A	2	N35A	66
N34A	4		
		W50A	>150
F50A	1	I51A	4
T51A	1	N52A	>150

Residue	IC50 (mut)	Residue	IC50 (mut)
VL	IC50 (wt)	VH	IC50 (wt)
S52A	1	T53A	9
S53A	1	Y54A	9
L54A	1	T55A	4
H55A	1	G56A	1
S56A	1	E57A	2
		P58A	1
Q89A	4	T59A	3
Q90A	3	Y60A	2
Y91A	14	A61S	1
S92A	1	A62S	1
T93A	1	D63A	1
V94A	2	F64A	1
P95A	3	K65A	1
W96A	>150	R66A	1
T97A	1		
		Y99A	>150
		P100A	38
		H101A	4
		Y102A	4
		Y103A	5
		G104A	2
		S105A	1
		S106A	>150
		H107A	2
		W108A	>150
		Y109A	19
		F110A	25
		D111A	2

All variants are in the background of pY0192 ("wt"; see Figs. 9A-B). IC50's were determined in a competitive phage-ELISA assay.

The largest effects of Ala substitutions are seen in CDRs H1, H2, and H3, including Y27A (34-fold reduction in affinity), N31A, Y32A, W50A, N52A, Y99A, S106A and W108A (each >150-fold reduction); N35A (66-fold reduction), P100A (38-fold reduction) and F110A (25-fold reduction). In contrast, only one VL substitution had a large impact on binding affinity, W96A

10

(>150-fold reduction). These results point to the three VH CDRs as the main energetic determinants of Fab binding to VEGF, with some contribution from VL3.

Design of Second-Generation CDR Mutation Libraries: Two additional libraries which randomized existing residues in anti-VEGF version Y0192 were designed based upon inspection of the crystal structure. In VH2, residues 52-55 were randomized because they lie within the binding interface with VEGF. An additional region of the Fab, termed "CDR7" (see Fig. 10B), was also targeted for randomization because several residues in this loop, while not contacting VEGF, do have contacts with the VH loops of the antibody. These represented potential sites for affinity improvement through secondary effects upon the interface residues. Residues L72, T74, and S77 were randomized in this CDR7 library.

Also based upon the crystal structure, one of the original CDR libraries was reconstructed to re-test the potential for affinity maturation in the VH1 CDR. Residues 27, 28, and 30-32 were randomized using the new Y0192 background.

Second-Generation Selections of Anti-VEGF Libraries: Based on Ala-scan results as well as the crystal structure of the antigen-antibody (F(ab)-12) complex, a total of seventeen libraries were constructed using the pY0192 template and stop-template oligonucleotides (which code for a stop codon at the sites targeted for randomization) YC-80, YC-100, YC-102, HL-263, and HL-264 (Table 9 above). The corresponding randomization oligonucleotides (which employ NNS at the sites targeted for randomization) were YC81, YC-101, YC-103, HL-265, and HL-266 (Table 10 above). The resulting transformants yielded libraries with complexities ranging from 6 x 10⁷ to 5 x 10⁸ which suggests that the libraries were comprehensive in covering all possible variants. Phage libraries were sorted for 7-8 rounds using conditions as described in Table 12 below.

Table 12: Conditions for Secondary Selections of Fab Variants

Round of Selection	Incubation Time (hr)	Incubation Solution	Incubation Temp. (°C)
1	0	0	room temp.
2	1	ELISA buffer	room temp.
3	2	1 μM VEGF/ELISA	room temp.

30

25

5

4	18	1 μM VEGF/ELISA	room temp.
5	37	1 μM VEGF/ELISA	room temp.
6	17 hr @ room temp./ 30 hr @ 37° C	1 μM VEGF/ELISA	room temp./37°C
7	63	1 μM VEGF/ELISA	37°C
8	121	1 μM VEGF/ELISA	37°C

ELISA buffer contained 0.5% bovine serum albumin and 0.05% TWEEN 20[™] in PBS. VEGF was included in the incubation buffer to minimize rebinding of phages to VEGF coated on the surface of the plate. Sorting of these libraries yielded phage enrichments over 7 to 8 rounds of selection.

Phage-ELISA Assays of Second Generation Clones: After eight round of selections, ten to twenty clones from each library were isolated from carbenicillin containing plates harboring *E. coli* (XL1) colonies which had been infected with an eluted phage pool. Colonies were isolated and grown with helper phage to obtain single-stranded DNA for sequencing. CDR substitutions selected for more favorable binding to VEGF were deduced from the DNA sequences of phagemid clones. A sampling of selected clones is shown in Table 13 below.

Table 13: Protein Sequences of Anti-VEGF Variants from Second Generation Fab-Phage Libraries

Variants from library YC-81		
Name	VH3 sequence (residues 99-111)	
Y0238-1	YPYYRGTSHWYFD (SEQ ID NO:56)	
Y0238-2	YPYYINKSHWYFD (SEQ ID NO:57)	
Y0238-3	YPYYYGTSHWYFD (SEQ ID NO:58)	
Y0238-4	YPYYYNQSHWYFD (SEQ ID NO:59)	
Y0238-5	YPYYIAKSHWYFD (SEQ ID NO:60)	
Y0238-6	YPYYRDNSHWYFD (SEQ ID NO:61)	
Y0238-7	YPYYWGTSHWYFD (SEQ ID NO:62)	

Y0238-8	YPYYRQNSHWYFD (SEQ ID NO:63)
Y0238-9	YPYYRQSSHWYFD (SEQ ID NO:64)
Y0238-10	YPYYRNTSHWYFD (SEQ ID NO:65)
Y0238-11	YPYYKNTSHWYFD (SEQ ID NO:66)
Y0238-12	YPYYIERSHWYFD (SEQ ID NO:67)
Y0228-21	YPYYRNASHWYFD (SEQ ID NO:68)
Y0228-22	YPYYTTRSHWYFD (SEQ ID NO:69)
Y0228-23	YPYYEGSSHWYFD (SEQ ID NO:70)
Y0228-24	YPYYRQRGHWYFD (SEQ ID NO:71)
Y0228-26	YPYYTGRSHWYFD (SEQ ID NO:72)
Y0228-27	YPYYTNTSHWYFD (SEQ ID NO:73)
Y0228-28	YPYYRKGSHWYFD (SEQ ID NO:74)
Y0228-29	YPYYTGSSHWYFD (SEQ ID NO:75)
Y0228-30	YPYYRSGSHWYFD (SEQ ID NO:76)
Y0229-20	YPYYTNRSHWYFD (SEQ ID NO:77)
Y0229-21	YPYYRNSSHWYFD (SEQ ID NO:78)
Y0229-22	YPYYKESSHWYFD (SEQ ID NO:79)
Y0229-23	YPYYRDASHWYFD (SEQ ID NO:80)
Y0229-24	YPYYRQKGHWYFD (SEQ ID NO:81)
Y0229-25	YPYYKGGSHWYFD (SEQ ID NO:82)
Y0229-26	YPYYYGASHWYFD (SEQ ID NO:83)
Y0229-27	YPYYRGESHWYFD (SEQ ID NO:84)
Y0229-28	YPYYRSTSHWYFD (SEQ ID NO:85)
Variants fro	om library HL-265
Name	VH1 sequence (residue 26-35)
Y0243-1	GYDFTHYGMN (5/10 clones) (SEQ ID NO:86)
Y0243-2	GYEFQHYGMN (SEQ ID NO:87)

Y0243-3	GYEFTHYGMN (SEQ ID NO:88)		
Y0243-4	GYDFGHYGMN (SEQ ID NO:89)		
Y0243-5	GYDFSHYGMN (SEQ ID NO:90)		
Y0243-6	GYEFSHYGMN (SEQ ID NO:91)		
Variants from library YC-101			
Name	VH "CDR7" sequence (residues 70-79)		
Y0244-1	FSVDVSKSTA (SEQ ID NO:92)		
Y0244-2	FSLDKSKSTA (SEQ ID NO:93)		
Y0244-3	FSLDVWKSTA (SEQ ID NO:94)		
Y0244-4	FSIDKSKSTA (:95)		

The sequence of the randomized region only is shown as deduced from DNA sequencing.

When a number of clones were tested along with the parent clone pY0192 in phage-ELISA assay, none showed a distinctive improvement over the parental clone. This could be explained by the time-scale on which the assay was performed (< 3 hours).

In order to quantify improvement in antigen binding over parent clone, several anti-VEGF variants' DNA were transformed into *E. coli* strain 34B8, expressed as Fab, and purified by passing the periplasmic shockate through a protein G column (Pharmacia) as described in Example 2 above.

CDR Combination Variants: To improve VEGF binding affinity further, mutations found by phage display were combined in different CDRs to create multiple-CDR mutants. In particular, the mutations identified in the most affinity-improved phage variants from VH1, VH2, and VH3 libraries were combined (Table 14) in order to test for additivity of their contributions to binding affinity.

25

25

Table 14: Combination CDR Anti-VEGF Variants

Name	Parent clone	Mutagenesis oligo/ comments	Sequence
Y0313-1	Y0243-1	YC-115 (VH3: H101Y and S105T)	5'-GCAAAGTACCCGTACTATTATGGGAC GAGCCACTGGTATTTC-3' (SEQ ID NO:96)
Y0317	Y0313-1	YC-108 (revert VL1 back to wild type)	5'-GTCACCATCACCTGCAGCGCAAGTCA GGATATTAGCAACTATTTAAAC-3' (SEQ ID NO:97)
Y0313-3	Y0238-3	YC-116 (VH3; T105S)	5'-CCGTACTATTATGGGAGCAGCCACTG GTATTTC-3' (SEQ ID NO:98)

Mutations from the indicated parental vectors were combined with those from the indicated oligonucleotide by site-directed mutagenesis to yield the combination variants listed.

Version Y0317 is equivalent to Y0313-1 except that the background mutation in VL1 was removed and its sequence reverted back to that in pY0101. The effects of mutating H101Y and S105T were tested by constructing a reversion mutant from Y0238-3.

BIAcore Analysis: The VEGF-binding affinities of Fab fragments were calculated from association and dissociation rate constants measured using a BIAcore-2000™ surface plasmon resonance system (BIAcore, Inc., Piscataway, NJ). A biosensor chip was activated for covalent coupling of VEGF using N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimidenydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's (BIAcore, Inc., Piscataway, NJ) instructions. VEGF was buffered exchanged into 20 mM sodium acetate, pH 4.8 and diluted to approximately 50 μg/mL. An aliquot (35 μL) was injected at a flow rate of 2 μL/min to achieve approximately 700-1400 response units (RU) of coupled protein. Finally, 1 M ethanolamine was injected as a blocking agent.

For kinetics measurements, two-fold serial dilutions of Fab were injected in PBS/TWEEN[™] buffer (0.05% TWEEN 20[™] in phosphate buffered saline) at 25° C at a flow rate of 10 μL/min. On rates and off rates were calculated using standard protocols (Karlsson *et al. J. Immun. Methods* 145:229-240 (1991)). Equilibrium dissociation constants, Kd's from surface plasmon resonance (SPR) measurements were calculated as koff/kon. Data are shown in Table 15 below.

10
i. al
1, , į
4. A.
115
31
j: 414
ş. i
الم الم
20

30

5

Table 15: Kinetics of Fab-VEGF binding from BlAcore™measurements				
Variant	Kon (10⁴/M/s)	koff (10⁴/s)	Kd (n <u>M</u>)	Kd (wt) / Kd (mut)
Y0244-1	3.4	2.7	8	3.6
Y0244-4	5.2	1.7	3.3	0.9
Y0243-1	6.7	0.45	0.7	4.1
Y0238-3	1.7	≤0.04 [*]	≤0.2	≥14 °
Y0238-7	1.5	≤0.06*	≤0.4	≥7.3 [*]
Y0238-10	1.6	0.09	0.6	4.8
Y0238-5	0.8	0.08	0.9	3.2
Y0238-1	2.6	0.09	0.4	7.3
Y0313-1	3.5	≤0.054*	<u>≤</u> 0.15 [*]	≥20°
Y0313-3	1.2	0.081	0.65	4.5

^{*} The dissociation rate observed probably reflects an upper limit for the true dissociation rate in these experiments, since the off-rate is approaching the limit of detection by BIAcore.

The BIAcore™ data in Table 15 show that several variants had improved affinity over Y0192. For example, a CDRH1 variant, Y0243-1, showed 4.1 fold enhanced affinity, arising from mutations T28D and N31H. Variant Y0238-3 showed at least a 14 fold improvement in binding affinity over Y0192. Both CDRH3 mutations contribute to the improved affinity of Y0238-3 because reversion of T105 to S (variant Y0313-3) reduces the affinity of Y0238-3 from 0.15nM to 0.65 nM (see Table 15). The greater affinity enhancement relative to Y0192 was seen for Y0313-1, which contained CDRH3 mutations combined with CDRH1 mutations.

Cell-Based Assay of VEGF Inhibition: Several versions of the A4.6.1 anti-VEGF antibody were tested for their ability to antagonize VEGF (recombinant; version 1-165) in induction of the growth of HuVECs (human umbilical vein endothelial cells). The 96-well plates were seeded with 1000 HuVECs per well and fasted in assay medium (F12:DMEM 50:50 supplemented with 1.5% diafiltered fetal bovine serum) for 24 h. The concentration of VEGF used for inducing the cells was determined by first titrating for the amount of VEGF that can stimulate 80% of maximal DNA synthesis. Fresh assay medium containing fixed amounts of VEGF (0.2 nM final concentration),

10

and increasing concentrations of anti-VEGF Fab or Mab were then added. After 40 h of incubation, DNA synthesis was measured by incorporation of tritiated thymidine. Cells were pulsed with 0.5 μ Ci per well of [3H]-thymidine for 24 h and harvested for counting, using a TopCount gamma counter.

The results (Fig. 11) show that the full-length IgG form of F(ab)-12 was significantly more potent in inhibiting VEGF activity than the Fab form (here, Y0192 was used). However, both variants Y0238-3 and Y0313-1 showed even more potent inhibition of VEGF activity than either the Y0192 Fab or F(ab)-12 Mab. Comparing the Fab forms, variant Y0313-1 appeared >30-fold more potent than the wild-type Fab. It should be noted that the amount of VEGF (0.2 nM) used in this assay is potentially limiting for determination of an accurate IC50 for the mutant. For example, if the binding affinity (Kd) of the mutant is in fact < 0.2 nM, the IC50 in this experiment will appear higher than under conditions of lower VEGF concentration. The result therefore supports the conclusion that the affinity-improved variant is at least 30-fold improved in affinity for VEGF, and that it effectively blocks VEGF activity *in vitro*. Since the variant Y0317 differs from Y0313-1 only in the reversion of the VL1 sequence to wild-type (Fig. 10A), it is predicted that Y0317 will have similar activity to Y0313-1.

Variant Y0317 (Fab) and humanized variant F(ab)-12 from Example 1 (full length and Fab) were compared for their ability to inhibit bovine capillary endothelial cell proliferation in response to a near maximally effective concentration of VEGF using the assay described in Example 1. As illustrated in Figure 12, Y0317 was markedly more effective at inhibiting bovine capillary endothelial cell proliferation than the full length and Fab forms of F(ab)-12 in this assay. The Y0317 affinity matured Fab demonstrated an ED50 value in this assay which was at least about 20 fold lower than F(ab)-12 Fab.

WHAT IS CLAIMED IS:

- 1. A humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about 1 x 10^{-8} M.
- 2. A humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about 5 x 10^{-9} M.
- 3. A humanized anti-VEGF antibody which has an ED50 value of no more than about 5nM for inhibiting VEGF-induced proliferation of endothelial cells *in vitro*.
- 4. A humanized anti-VEGF antibody which inhibits VEGF-induced angiogenesis in vivo.
- 5. The humanized anti-VEGF antibody of claim 4 wherein 5mg/kg of the antibody inhibits at least about 50% of tumor growth in an A673 *in vivo* tumor model.
- 6. The humanized anti-VEGF antibody of claim 1 having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYX_1FTX_2YGMN , wherein X_1 is T or D and X_2 is N or H; SEQ ID NO:128), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 ($YPX_1YYGX_2SHWYFDV$, wherein X_1 is Y or H and X_2 is S or T; SEQ ID NO:129).
- 7. The humanized anti-VEGF antibody of claim 6 comprising the amino acid sequence of SEQ ID NO:7.
- 8. The humanized anti-VEGF antibody of claim 6 having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYTFTNYGMN; SEQ ID NO:1), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPHYYGSSHWYFDV; SEQ ID NO:3).

- 9. The humanized anti-VEGF antibody of claim 1 having a light chain variable domain comprising the following hypervariable region amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS; SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6).
- 10. The humanized anti-VEGF antibody of claim 9 comprising the amino acid sequence of SEQ ID NO:8.
- 11. The humanized anti-VEGF antibody of claim 1 having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.
- 12. An anti-VEGF antibody light chain variable domain comprising the amino acid sequence: DIQX₁TQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ KPGKAPKVLIYFTSSLHSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR (SEQ ID NO:124), wherein X₁ is M or L.
- 13. An anti-VEGF antibody heavy chain variable domain comprising the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGYX $_1$ FTX $_2$ YGMNWVRQAPGKGLEWVGWINTYTGEPT YAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPX $_3$ YYGX $_4$ SHWYFDVWGQGTLV TVSS (SEQ ID NO:125), wherein X $_1$ is T or D; X $_2$ is N or H; X $_3$ is Y or H and X $_4$ is S or T.
- 14. A variant of a parent anti-VEGF antibody, wherein said variant binds human VEGF and comprises an amino acid substitution in a hypervariable region of a heavy chain variable domain of said parent antibody.
- 15. The variant of claim 14 wherein said parent antibody is a human or humanized antibody.
- 16. The variant of claim 14 which binds human VEGF with a K_d value of no more than about $1 \times 10^{-8} M$.

- 17. The variant of claim 14 which binds human VEGF with a K_d value of no more than about $5 \times 10^{-9} M$.
- 18. The variant of claim 14 wherein the substitution is in CDRH1 of the heavy chain variable domain.
- 19. The variant of claim 14 wherein the substitution is in CDRH3 of the heavy chain variable domain.
- 20. The variant of claim 14 which has amino acid substitutions in both CDRH1 and CDRH3.
- 21. The variant of claim 14 which binds human VEGF with a K_d value less than that of said parent antibody.
- 22. The variant of claim 14 which has an ED50 value for inhibiting VEGF-induced proliferation of endothelial cells *in vitro* which is at least about 10 fold lower than that of said parent antibody.
- 23. The variant of claim 18 wherein the CDRH1 comprises the amino acid sequence: GYDFTHYGMN (SEQ ID NO:126)
- 24. The variant of claim 19 wherein the CDRH3 comprises the amino acid sequence: YPYYYGTSHWYFDV (SEQ ID NO:127).
- 25. The variant of claim 14 wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:116.
- 26. The variant of claim 25 further comprising the light chain variable domain amino acid sequence of SEQ ID NO:124.

- 27. The variant of claim 26 comprising the light chain variable domain amino acid sequence of SEQ ID NO:115.
- 28. The humanized anti-VEGF antibody of claim 1 which is a full length antibody.
- 29. The humanized anti-VEGF antibody of claim 28 which is a human IgG.
- 30. The humanized anti-VEGF antibody of claim 1 which is an antibody fragment.
- 31. The antibody fragment of claim 30 which is a Fab.
- 32. A composition comprising the humanized anti-VEGF antibody of claim 1 and a pharmaceutically acceptable carrier.
- 33. A composition comprising the variant anti-VEGF antibody of claim 14 and a pharmaceutically acceptable carrier.
- 34. Isolated nucleic acid encoding the antibody of claim 1.
- 35. A vector comprising the nucleic acid of claim 34.
- 36. A host cell comprising the vector of claim 35.
- 37. A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.
- 38. The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.

- 39. A method for inhibiting VEGF-induced angiogenesis in a mammal comprising administering a therapeutically effective amount of the humanized anti-VEGF antibody of claim 1 to the mammal.
- 40. The method of claim 39 wherein the mammal is a human.
- 41. The method of claim 39 wherein the mammal has a tumor.
- 42. The method of claim 39 wherein the mammal has a retinal disorder.

ANTI-VEGF ANTIBODIES


Abstract of the Disclosure

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells *in vitro*; and inhibit tumor growth *in vivo*.

Variable Heavy

A4.6.1	EIQLVQSGPELKQPGETVRISCKAS <u>GYTFTNYGMN</u> WVKQAPGKGLKWMG	
F(ab)-12	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVG	
humIII	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVS 1 10 20 30 40	
A4.6.1	WINTYTGEPTYAADFKRRFTFSLETSASTAYLQISNLKNDDTATYFCAK * * *** *** * *	Fig. 1A
F(ab)-12	WINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAK * **** *** *** * * * * * * * * *	3
humIII	VISGDGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 50 a 60 70 80 abc 90	•
A4.6.1	YPHYYGSSHWYFDVWGAGTTVTVSS (SEQ ID NO:9)	
F(ab)-12	YPHYYGSSHWYFDVWGQGTLVTVSS (SEQ ID NO:7)	
humIII	GFDYWGQGTLVTVSS (SEQ ID NO: 11)	
	Variable Light	
A4.6.1	DIQMTQTTSSLSASLGDRVIISC <u>SASODISNYLN</u> WYQQKPDGTVKVLIY ** ** ***	
F(ab)-12	DIQMTQSPSSLSASVGDRVTITC <u>SASODISNYLN</u> WYQQKPGKAPKVLIY * * * *	
humKI	DIQMTQSPSSLSASVGDRVTITCRASQSISNYLAWYQQKPGKAPKLLIY 1 10 20 30 40	
		Fig. 1B
A4.6.1	FTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYC <u>OOYSTVPWT</u> F	
F(ab)-12	FTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCOOYSTVPWTF ** *	
humKI	AASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSLPWTF 50 60 70 80 90	
A4.6.1	GGGTKLEIKR (SEQ ID NO: ID)	
F(ab)-12	GQGTKVEIKR (SEQ ID NO:8)	
humKI	GQGTKVEIKR (SEQ ID NO: 12)	,

Fig. 2







Fig. 4

V_L domain

A4.6.1	DIQMTQTTSSLSASLGDRVIISCSASQDISNYLNWYQQKP
hu2.0	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
hu2.10	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
A4.6.1	Fig. 5A 50 60 70 80 DGTVKVLIYFTSSLHSGVPSRFSGSGSGTDYSLTISNLEP
hu2.0	**** * * * * * * * * * * * * * * * * *
	•
hu2.10	GKAPKLLIYFTSSLHSGVPSRFSGSGSGTDYTLTISSLQP
	90 100
A4.6.1	EDIATYYCQQYSTVPWTFGGGTKLEIK (SEQ 1D NO:10)
hu2.0	EDFATYYCQQYSTVPWTFGQGTKVEIK (SEQ 10 NO:13)
hu2.10	EDFATYYCQQYSTVPWTFGQGTKVEIK (SEQIDNO: 15)
	- V _H domain
A4.6.1	* * ** * *** *
hu2.0	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA •
hu2.10	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWIRQA
A4.6.1	50 a 60 70 80 Fig. 5B PGKGLKWMGWINTYTGEPTYAADFKRRFTFSLETSASTAYL * * * * * * * * *
hu2.0	PGKGLEWVGWINTYTGEPTYAADFKRRFTISRDNSKNTLYL
hu2.10	PGKGLEWVGWINTYTGEPTYAADFKRRFTISLDTSASTVYL
A4.6.1	abc 90 100abcdef 110 QISNLKNDDTATYFCAKYPHYYGSSHWYFDVWGAGTTVTVSS (SEQ ID NO:9)
	*** ***
	QMNSLRAEDTAVYYCARYPHYYGSSHWYFDVWGQGTLVTVSS (SEQ ID NO: 14)
hu2.10	QMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS (SEQ (D NO:16)






Fig. 7

- GITGITAIT AAGCITIGGA GAITAICGIC ACIGCAAIGC CTAATAGCAG TTCGAAACCT CAACAATAAA TCATTGCTGA AGTAACGACT TCTCCATACT TTGGATAAGG AAATACAGAC ATGAAAAATC TACTTTTAG TTTATGTCTG CTTAAGTIGA AGAGGIAIGA AACCIAITCC GAATTCAACT
- TGCTGCTATG AGCATTCCTG TCGTAAGGAC GCCCGATGCC CGGGCTACGG ACGAGGTAAA TGCTCCATTT GGGCGCTGT CCCCGCGACA GGTTGATTGA TCAGGTAGAG CCAACTAACT AGTCCATCTC GACCAACAGC CTGGTTGTCG CCGCGTTTTA GGCGCAAAAT TTCGCAATAT AAGCGTTATA 101
- CCGGCTCTGA AGCTGTCATA AAGTTGTCAC TTCAACAGTG TCGACAGTAT TCTTTTCAAC AGAAAAGTTG AAAAAGTTAA TTTTTCAATT CCTCGTCAGT TAACTICGIA GGAGCAGICA ATTGAAGCAT ATTTCTTCAA TAAAGAAGTT GCGCTAATGC CGCGATTACG CCTCGACGAC GGAGCTGCTG 201
- M etLysLysAsn TAGAGGITGA GGTGAITITA TGAAAAGAA CCACTAAAT ACTITITITI ATCTCCAACT CCCCTAGGAG CICGGIACCC GGGGAICCIC TAAACATTGA TCTTAAGCTC GAGCCATGGG ATTTGTAACT AGAATTCGAG ATATCAGCGA AACAAAATA AAAAATTACA TTTTTAATGT TTGTTTTAT TATAGICGCT 301
- Begin stII signal sequence CGTACGCTGA TATCCAGTTG ACCCAGTCCC CGAGCTCCCT GTCCGCCTCT CAGGCGGAGA GCATGCGACT ATAGGTCAAC TGGGTCAGGG GCTCGAGGGA GCTACAAACG CGATGTTTGC TTTTTCTATT AAAAAGATAA CTATGTTCGT GATACAAGCA GAAGAACGTA CTTCTTGCAT TATCGCATTT ATAGCGTAAA 401
- LeuLeuAlaS erMetPheVa 1PheSerIle AlaThrAsnA laTyrAlaAs pIleGlnLeu ThrGlnSerP roSerSerLe uSerAlaSer Begin light chain IlealaPhe
- AAACTACTGA TTTGATGACT CTATTTAAAC TGGTATCAAC AGAAACCAGG AAAAGCTCCG TTTTCGAGGC TCTTTGGTCC GATAAATTTG ACCATAGTTG ATATTAGCAA TATAATCGTT GCAAGTCAGG CGTTCAGTCC GGGTCACCAT CACCTGCAGC GTGGACGTCG CCCAGTGGTA GTGGGCGATA CACCCGCTAT 501
 - LysLeuLeuIle nTyrLeuAsn TrpTyrGlnG lnLysProGl yLysAlaPro TCCGGTTCTG GGACGGATTA CACTCTGACC ATCAGCAGTC ValGlyAspA rgValThril eThrCysSer AlaSerGlnA spileSerAs 12
- SerGlySerG lyThrAspTy rThrLeuThr IleSerSerL euGlnProGlu ACGTCGGTCT GTGAGACTGG TAGTCGTCAG CCTGCCTAAT AGGCCAAGAC gPheSerGly GAAGAGACCT CTTCTCTGGA TyrPheTh rSerSerLeu HisSerGlyV alProSerAr TCCCTTCTCG AGGGAAGAGC CACTCTGGAG GTGAGACCTC CICCICICIC GAGGAGAGAG 601 TTTACTTCAC AAATGAAGTG
- AspPheAla ThrTyrTyrC ysGlnGlnTy rSerThrVal ProTrpThrP heGlyGlnGl yThrLysVal GluIleLysA rgThrValAl aAlaProSer TIGGACAGGG TACCAAGGIG GAGAICAAAC GAACIGIGGC CTTGACACCG CTCTAGTTTG AACCTGTCCC ATGGTTCCAC GTCAACAGTA TAGCACCGTG CCGTGGACGT GGCACCTGCA ATCGTGGCAC CAGTTGTCAT ACTTATTACT TGAATAATGA 701 AGACTTCGCA TCTGAAGCGT 82
- snPheTyrPr oArgGluAla LysValGlnTrp AAAGTACAGT TTTCATGTCA CAGAGAGGCC GICICICGG TGAAGATAGG ACTICIATCC lyThrAlaSe rValValCys LeuLeuAsnA CTGCTGAATA GACGACTTAT GAACTGCTTC TGTTGTGTGC ACAACACACG CTTGACGAAG TCCCGCCATC TGATGAGCAG TTGAAATCTG AGGGCGGTAG ACTACTCGTC AACTTTAGAC GICTICATCT CAGAAGTAGA 801
 - GGGACTGCGA CCCTGACGCT GCAAGGACAG CACCTACAGC CTCAGCAGCA GAGTCGTCGT GTGGATGTCG CGTTCCTGTC CTCGTCCTGT GAGCAGGACA GAGTGTCACA CTCACAGTGT heproprose raspGluGln LeuLysSerG CAATCGGGTA ACTCCCAGGA TGAGGGTCCT GTTAGCCCAT TAACGCCCTC ATTGCGGGAG CCTTCCACCT ValPhelleP GGAAGGTGGA 115 901
- GAGCTCGCCC GTCACAAGA GCTTCAACAG GAAGTCACCC ATCAGGGCCT CTACGCCTGC GACTACGAGA AACACAAAGT Lysvalas GAGCAAAGCA 149 1001

snSerGlnGl

pAsnAlaLeu GlnSerGlyA

uservalThr GluGlnAspS erLysAspSe rThrTyrSer LeuSerSerT

hrleuThrleu

SerLysAla AspTyrGluL ysHisLysVa lTyrAlaCys GluValThrH isGlnGlyLe uSerSerPro ValThrLysS erPheAsnAr CGAAGTTGTC CAGTGTTTCT CTCGAGCGGG CTTCAGTGGG TAGTCCCGGA GATGCGGACG TTGTGTTTCA CTGATGCTCT CTCGTTTCGT 182

- LysAsnIleAla TTCTTATAGC -23 MetLys TTTTATGAAA ATTCGACTAG GAGATGCGGC CTGCGTAGCA CCGGGATCAT GCGTTGATCA GCATTTTTCC CATAGATCTC CAACTCCACT AAAATACTTT GTTGAGGTGA GACGCATCGT GGCCCTACTA CGGAACTAGT GGTAAAAAGG GTATCTAGAG Begin stII signal sequence 1101 TAAGCTGATC CTCTACGCCG ပုံ ဝ 215
- lnProGlyGly AGCCAGGGG GlyLeuValG CCGGACCACG GGCCTGGTGC CAGACCGCCA uSerGlyGly GTCTGGCGGT AAACGCGTAC GCTGAGGTTC AGCTGGTGGA TITGCGCATG CGACTCCAAG ICGACCACCI PheLeuLe uAlaSerMet PheValPheS erIleAlaTh rAsnAlaTyr AlaGluValG InLeuValGl Begin heavy chain TGCATCTATG TTCGTTTTTT CTATTGCTAC GTAAAGAAGA ACGTAGATAC AAGCAAAAAA GATAACGATG CATTTCTTCT 1201 -17
 - ATGGGTTGGA GCCCCGGGTA AGGGCCTGGA TCCCGGACCT CGGGGCCCAT GTATGAACTG GATCCGTCAG CATACTIGAC CTAGGCAGIC ACCAACTATG TGGTTGATAC CAGCITCIGG CTATACCITC GATATGGAAG GTCGAAGACC TTGTCCTGTG AACAGGACAC GAGTGAGGCA CTCACTCCGT 1301
 - urrpValGly ATGGACGTCT SerLeuArg LeuSerCysA laAlaSerGl yTyrThrPhe ThrAsnTyrG lyMetAsnTr pIleArgGln AlaProGlyL ysGlyLeuGl GTTGTGTCAA gargpheThr IleSeralaa spThrSerSe rasnThrVal CAACACAGIT TCGTTTTACT ATAICTGCAG ACACCTCCAG TGTGGAGGTC TATAGACGTC AGCAAAATGA TATGCTGCGG ATTTCAAACG TAAAGTTTGC Tyralaalaa spPheLysar ATACGACGCC TGAACCGACC ACTIGGCIGG yGluProThr CCTATACCGG hrTyrThrGl GGATATGGCC TrplleAsnT TGGATTAACA ACCTAATTGT 1401 20 17
- rpclyclngly CCCCAGTTCC GGGGTCAAGG AsnSerLe uArgAlaGlu AspThrAlaV alTyrTyrCy sAlaLysTyr ProHisTyrT yrGlySerSe rHisTrpTyr PheAspValT TICGACGICT GGTGACCATA AAGCTGCAGA CCACTGGTAT CCGCACTAIT AIGGGAGCAG GGCGTGATAA TACCCTCGTC TCTATTACTG TGCAAAGTAC ACGTTTCATG AGATAATGAC GACACTGCCG CTGTGACGGC GCGCGCTGAG CGCGCGACTC ACTTGTCGGA TGAACAGCCT 1501 84
- GGCCCTGGGC aAlaLeuGly GGGCACAGC CCCCGTGTCG SerThrSerG lyGlyThrAl CTCCTCCAAG AGCACCTCTG TCGTGGAGAC ThrLeuVal ThrValSerS erAlaSerTh rLysGlyPro SerValPheP roLeuAlaPr oSerSerLys GAGGAGGTTC CCCTGGCACC GGGACCGTGG TCGGTCTTCC AGCCAGAAGG GTTCCCGGGT CAAGGGCCCA CGGCCTCCAC ACCGTCTCCT TGGCAGAGGA AACCCTGGTC TTGGGACCAG 1601 117
- LeuGlnSerSer ValThrValS erTrpAsnSe rGlyAlaLeu ThrSerGlyV alHisThrPh eProAlaVal CCCGGCTGTC GGGCCGACAG TGCACACCTT ACGIGIGGAA AGGCGCCCTG ACCAGCGGCG TGGTCGCCGC TCCGCGGGAC GTGACGGTGT CGTGGAACTC GCACCTTGAG CACTGCCACA CysLeuVall ysAspTyrPh eProGluPro TGCCTGGTCA AGGACTACTT CCCCGAACCG GGGCTTGGC TCCTGATGAA ACGGACCAGT 150 1701
- GCAACACCAA CCTACATCTG CAACGTGAAT CACAAGCCCA GGATGTAGAC GTTGCACTTA GTGTTCGGGT sAsnValAsn HisLysProS GlyLeuTy rSerLeuSer SerValValT hrValProSe rSerSerLeu GlyThrGlnT hrTyrIleCy GGCACCCAGA CCGTGGGTCT GTCGTCGAAC CAGCAGCTTG CCGTGCCCTC GGCACGGGAG CAGGACTCTA CTCCCTCAGC AGCGTGGTGA TCGCACCACT GAGGGAGTCG GTCCTGAGAT 1801 184
- CTACCGTTTG sMetAlaAsn GGTGATTTTG ATTATGAAAA sAspLysThr HisLeuAM*S erGlyGlyGl ySerGlySer GlyAspPheA spTyrGluLy TAATACTTT CCACTAAAAC TGACAAAACT CACCTCTAGA GTGGCGGTGG CTCTGGTTCC ACTGTTTTGA GTGGAGATCT CACCGCCACC GAGACCAAGG Begin g3p domain GGTTTAGAAC CCAAATCTTG ValAspLys LysValGluP roLysSerCy AAAGTTGAGC TTTCAACTCG GGTCGACAAG CCAGCTGTTC 217 1901
- AlaAsnLysG lyAlaMetTh rGluAsnAla AspGluAsnA laLeuGlnSe rAspAlaLys GlyLysLeuA spSerValAl aThrAspTyr GlyAlaAlaIle CCACGACGAT TACTGATTAC ATGACTAATG TAAGACAGCG GATGAAAACG CGCTACAGTC TGACGCTAAA GGCAAACTTG ATTCTGTCGC CCGTTTGAAC CTACTTTTGC GCGATGTCAG ACTGCGATTT end light chain GGGCTATGAC CGAAAATGCC GCTTTTACGG CCCGATACTG GCTAATAAGG CGATTATTCC 250 2001
- alGlyAspGly AGCCACTGCC TCGGTGACGG ATGGCTCAAG TACCGAGTIC yAsnGlyAla ThrGlyAspP heAlaGlySe rAsnSerGln MetAlaGlnV CATTGGTGAC GITTCCGGCC ITGCTAATGG TAATGGTGCT ACTGGTGATT TTGCTGGCTC TAATTCCCAA TGACCACTAA AACGACCGAG ATTAAGGGTT ATTACCACGA AACGATTACC ValSerGlyL euAlaAsnGl CAAAGGCCGG elleGlyAsp GTAACCACTG TCGATGGTTT AspGlyPh AGCTACCAAA 2101 284
- TAAACCATAT **YLYSProTyr** TTAGCGCTGG AATCGCGACC ProPheValP heSerAlaGl GGAAAACAGA CCTTTTGTCT GAGTTAGCCA ACTTACAGCG CTCAATCGGT TGAATGTCGC ProLeuMeta snasnPhear gGlnTyrLeu ProSerLeuP roGlnSerVa 1GluCysArg CCTTCCCTCC GGAAGGGAGG AGTTATAAAT CCTTTAATGA ATAATTTCCG TCAATATTTA TATTAAAGGC GGAAATTACT Aspasaser TGATAATTCA ACTATTAAGT 317 2201

- ThrPheAlaAsn rValPheSer ACATAAAAGA TGTATTTCT CCTTTATGTA GGAAATACAT pLysileAsn LeuPheArgG lyValPheAl aPheLeuLeu TyrValAlaT hrPheMetTy CAAAATAAAC TTATTGGGGG GTGTCTTTGG GTTTCTTTTA TATGTTGCCA GTTTTATTTG AATAAGGCAC CACAGAAACG CAAAGAAAT ATACAAGGT CTTAAAAGAT AACTAACACT leAspCysAs TTGATTGTGA GAATTTTCTA GluPheSerI 2301
- ACGTACCTCG CCTTGTCTGC CTCCCCGCGT TGCGTCGCGG GGAACAGACG GAGGGGCGCA ACGCAGCGCC CCGCCCTATA TAATAAGGAG TCTTAATCAT GCCAGTTCTT TTGGCTAGCG ATTATTCCTC AGAATTAGIA CGGTCAAGAA AACCGATCGC ACATACTGCG TGTATGACGC 2401
- gasnlysglu seroc* (SEQ 10 NO: 100) IleLeuAr
- CTTAACCTCG GTTAGTTAAG AACGCCTCTT TTGCGGAGAA CAATCAATTC GAATTGGAGC ACCACTCCAA TGGTGAGGTT GGCACCTCGC TAACGGATTC SCCCGGTGGA GCTGGACTTA CCTTCGGCCG CCGTGGAGCG ATTGCCTAAG CGACCTGAAT GGAAGCCGGC end g3 protein CGGCCCACCT 2501
- TGCCCACGCG GGTCCTGGCC CCAGGACCGG CGCGTAGAGC CCGTCGCAAC GGCAGCGTTG GCGCATCTCG GCCGCACGCG CGGCGTGCGC CGCGTCCGCC ATCTCCAGCA GGAACCGTCT TGTATAGGTA GCGCAGGCGG TAGAGGTCGT CCTTGGCAGA ACATATCCAT CGTTTGGTTG GCAAACCAAC 2601
- ACTTCGCTGA TGAAGCGACT GCTCGCTTGC CGAGCGAACG CACCGATACG GICTTACTIA GIGGCIAIGC CAGAATGAAT TACTGGTTAG CCCCAACGGA ATGACCAATC GGGGTTGCCT CTAGGCTGGC CICCIGGGCC GAICCGACCG GAGGACCCGG TCCTGTCGTT TACTAGCACG AGGACAGCAA ATGATCGTGC 2701
- CCTGCACCAT GGACGTGGTA AAGTCAGCGC TTCAGTCGCG GGAAACGCGG GCATTTCAGA CCTTTGCGCC CGTAAAGTCT TTCCGTGTTT TGGACTCGTT GTTGTACTTA CCAGAAGCCA AAGGCACAAA GGTCTTCGGT CAACATGAAT ACCTGAGCAA AACGICIGCG TTGCAGACGC GCTGCTGCAA CGACGACGTT 2801
- GATTTTTCTC CTAAAAAGAG GACCCTGAGT CTGGGACTCA TAATTGCTTC GCGACCGTAA CGCTGGCATT ATTAACGAAG CTACATCTGT GATGTAGACA TGTGGAACAC GICCIACGAC GACCGAIGGG ACACCIIGIG CTGGCTACCC CAGGATGCTG TAGACGTAGC ATCTGCATCG ATACAAGGCC TATGTTCCGG 2901
- ATCCTCTCTC TAGGAGAGAG TATCGTGAGC ATAGCACTCG ACAAGTAGTA GTCATTGGGC CAGTAACCCG TGTTCATCAT TAACCGGGCA GCGGTCAACA AATGGGAGTG TTGCAAGGTC ATTGGCCCGT AACGTTCCAG CGCCAGTTGT TTACCCTCAC GCATCCATAC CGTAGGTATG TGGTCCCGCC ACCAGGGCGG 3001
- GGCCCGCTTT CCGGGCGAAA CCCTTAACAT GGGAATTGTA CTGGTTTGTC CTTTTTTGGC GAAAAAACCG GACCAAACAG GGCATCAAGT CCGTAGTTCA CTTACACGGA CAAAGTAGCC ATAGTAATGG GGGTACTTGT CTTTAAGGGG GAATGTGCCT GAAATTCCCC CCCATGAACA TATCATTACC GTTTCATCGG 3101
- GCTGATGAGC CGACTACTCG TCACGACCAC CGTCTGTAGA CACTTAGGGA AGTGCTGGTG GTGAATCGCT GCAGACATCT GGATGAACAG CCTACTTGTC AGCTGGACGC CGAAGACCTC TITGAGITGC ICGACCTGCG GCTTCTGGAG AAACTCAACG AGACATTAAC TCTGTAATTG TAGTCTTCGG ATCAGAAGCC 3201
- TCGAGTAAAA AATTGGTTAT TTAACCAATA TIGITAAAIC AGCICAITIT AACATTTGCA ATTATAAAAC AATTTTAAGC GCAATTTAAA AACAATTTAG CGTTAAATTT TTAAAATTCG TIGIAAACGI TAATATITIG GATCCGGAAA CTAGGCCTTT TTTACCGCAG AAATGGCGTC 3301
- GACTCCAACG AAAGAACGTG TTTCTTGCAC CAGGTGATAA GTCCACTATT TGGAACAAGA CCAACTCACA ACAAGGTCAA ACCTTGTTCT TGTTCCAGTT GGTTGAGTGT AAAAGAATAG ACCGAGATAG TTTTCTTATC TGGCTCTATC CTTATAAATC GAATATTTAG GGCAAAATCC CCGTTTTAGG 3401
- GTGATTTAGC CACTAAATCG ACGCCATTTC TGCCGTAAAG GGGGTCGAGG CCCCAGCTCC CAAGTTTTTT GTTCAAAAAA TGCACTTGGT AGTGGGATTA ACGIGAACCA TCACCCIAAT ATAGTCCCGA TACCGGGTGA ATGGCCCACT TATCAGGGCT TTTTGGCAG AAAAACCGTC AGTTTCCCGC TCAAAGGGCG 3501
- CGCTAGGGCG GCGATCCCGC AAGGAGCGGG TTCCTCGCCC AAGAAAGCGA TTCTTTCGCT AAAGGAAGGG TTTCCTTCCC ACGTGGCGAG TGCACCGCTC AAGCCGGCGA TICGGCCGCT TTGACGGGGA CTAAATCTCG AACTGCCCCT GATTTAGAGC GGGAGCCCCC CCCTCGGGGG GAACCCTAAA CTTGGGATTT 3601
- GCAAAGCCAC GACGGAGCGC CTGCCTCGCG CGTCCGGATC GCAGGCCTAG CTACAGGGCG GATGTCCCGC GGCGCGCGA ATTACGCGGC TAATGCGCCG CCGCCGCGCT regregrere ACCACCACAC CGACGCGCAT GCTGCGCGTA TAGCGGTCAC ATCGCCAGTG CTGGCAAGTG GACCGTTCAC 37.01
- CGCGCAGTCG CGGGCAGTCC GCCCGTCAGG CGGATGCCGG GAGCAGACAA CTCGTCTGTT ACAGACATTC GCCTACGGCC GGTCACAGCT TGTCTGTAAG CCAGTGTCGA CACATGCAGC TCCCGGAGAC GTGTACGTCG AGGGCCTCTG TTTGGAGACT AAACCTCTGA TACTGCCACT 3801 ATGACGGTGA

- GAAAGAACAT GTGAGCAAAA CICACGIGGI AIACGCCACA CITIAIGGCG IGICIACGCA IICCICITIT AIGGCGIAGI CCGCGAGAAG GCGAAGGAGC GAGIGACIGA GCGACGCGAG GGGTGTTGGC GGGTGTCGGG GCGCAGCCAT GACCCAGTCA CGTAGCGATA GCGGAGTGTA TACTGGCCTTA ACTATGCGGC ATCAGAGCAG ATTGTACTGA CCCACAACCG CCCACAGCCC CGCGTCGGTA CTGGGTCAGT GCATCGCTAT CGCCTCACAT ATGACCGAAT TGATACGCCG TAGTCTCGTC TAACATGACT CTCACTGACT GATAACGCAG CGCTTCCTCG GAAATACCGC ACAGATGCGT AAGGAGAAAA TACCGCATCA GGCGCTCTTC CIGCGGCGAG CGGIATCAGC ICACICAAAG GCGGIAAIAC GGIIAICCAC AGAAICAGGG TATGCGGTGT GGTCGTTCGG GAGTGCACCA GGGTGTTGGC 3901 4101 4001
 - CCAGCAAGCC GACGCCGCTC GCCATAGTCG AGTGAGTTTC CGCCATTATG CCAATAGGTG TCTTAGTCCC CTATTGCGTC CTTTCTTGTA CACTCGTTTT CGCTCAAGTC CAAAAATCGA CCATAGGCTC CGCCCCCTG ACGAGCATCA GCCGCGTTGC TGGCGTTTTT GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG 4201
- CCGGICGITI ICCGGICCII GGCAIIIIIC CGGCGCAACG ACCGCAAAAA GGIAICCGAG GCGGGGGGAC IGCICGIAGI GIIIIIAGCI GCGAGIICAG GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC GATACCAGGC GTTTCCCCCT AGAGGTGGCG AAACCCGACA GGACTATAAA 4301
 - TCTCCACCGC TITGGGCTGT CCTGAIAITI CIAIGGICCG CAAAGGGGGA CCTTCGAGGG AGCACGCGAG AGGACAAGGC IGGGACGGCG AAIGGCCTAI GGACAGGCGG AAAGAGGGAA GCCCTTCGCA CCGCGAAAGA GTATCGAGTG CGACATCCAT AGAGTCAAGC CACATCCAGC AAGCGAGGTT CGACCCGACA TTCGCTCCAA GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG GGCGCTTTCT CATAGCTCAC CCTGTCCGCC TITCTCCCTT CGGGAAGCGT 4401
- CTGGCAGCAG CACGIGCTIG GGGGGCAAGI CGGGCIGGCG ACGCGGAAIA GGCCATIGAI AGCAGAACIC AGGIIGGGCC AITCIGIGCI GAAIAGCGGI GACCGICGIC CTTATCGCCA CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGA GTGCACGAAC 4501
- CAGTATTTGG GGTGACCATT GICCIAATCG ICTCGCICCA TACATCCGCC ACGAIGICIC AAGAACTICA CCACCGGAIT GAIGCCGAIG IGAICTICCI GICAIAAACC CAGGATTAGC AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGGA CCACTGGTAA 4601
- ATAGACGEGA GACGACTICG GICAAIGGAA GCCITITICI CAACCAICGA GAACIAGGCC GITIGITIGG IGGCGACCAI CGCCACCAAA AAAACAAACG CITGAICCGG CAACAAACC ACCGCIGGIA GCGGIGGIII IIIIGIIIGC TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT 4701
- TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TICGICGICI AAIGCGCGIC IITITIICCI AGAGIICIIC IAGGAAACIA GAAAAGAIGC CCCAGACIGC GAGICACCII GCIITIGAGI GCAAIICCCI **AAGCAGCAGA** 4801
- TITIGGICAT GAGATIATCA AAAAGGATCT TCACCTAGAT CCTTITAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT AAACTIGGTC AAAACCAGTA CTCTAATAGT TITICCTAGA AGTGGATCTA GGAAAATTTA ATTTTTACTT CAAAATTTAG TTAGATTTCA TATATACTCA TTTGAACCAG 4901
- IGACAGTIAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG ACTGTCAATG GTTACGAATT AGTCACTCCG TGGATAGAGT CGCTAGACGA ATAAAGCAAG TAGGTATCAA CGGACTGAGG GGCAGCACAT CTATTGATGC TGACAGTTAC ATACGGGAGG 5101 5001
- GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA CGAATGGTAG ACCGGGGTCA CGACGTTACTT ATGGCGCTCT GGGTGCGAGT GGCCGAGGTC TAAATAGTCG TTATTTGGTC GGTCGGCCTT CAGAAGIGGI CCIGCAACII TAICCGCCIC CAICCAGICI AITAAIIGII GCCGGGAAGC IAGAGIAAGI AGIICGCCAG IIAAIAGIII TATGCCCTCC GGCCGAGCG 5201

GICTICACCA GGACGITGAA ATAGGCGGAG GTAGGTCAGA TAATTAACAA CGGCCCTTCG ATCTCATTCA TCAAGCGGTC AATTATCAAA

CCCGCCTCGC

- CGCTCGTCGT TIGGTATGGC TICATICAGC ICCGGTTCCC AACGAICAAG GCGAGTTACA CGCGTTGCAA CAACGGTAAC GACGTCCGTA GCACCACAGT GCGAGCAGCA AACCATACCG AAGTAAGTCG AGGCCAAGGG TTGCTAGTTC CGCTCAATGT GITGCCAITG CIGCAGGCAT CGIGGIGICA GCGCAACGTT 5301
- ACAACACGIT TITICGCCAA ICGAGGAAGC CAGGAGGCIA GCAACAGICI ICAITCAACC GGCGICACAA IAGIGAGIAC CAAIACCGIC AGTAAGTIGG CCGCAGIGIT ATCACICAIG TGIIGIGCAA AAAAGCGGII AGCICCIICG GICCICCGAI CGIIGICAGA TGATCCCCCA ACTAGGGGGT 5401
- ITCTCTTACT GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTA TGCGGCGACC GIGACGIRIT AAGAGAAIGA CAGIACGGIA GGCAIICIAC GAAAAGACAC IGACCACICA IGAGIIGGII CAGIAAGACI CIIAICACAI ACGCCGCIGG 5501 CACTGCATTA

- GCGAAAACTC CTCAACGAGA ACGGGCCGCA GIIGIGCCCI ATTAIGGCGC GGIGIAICGI CIIGAAAIII ICACGAGIAG IAACCIIIIG CAAGAAGCCC CGCIIIIGAG 5601 GAGITGCICT TGCCCGGCGI CAACACGGGA TAATAGGGG GGAGATAGCA GAACTITAAA AGTGCTCAIC ATIGGAAAAC GITCITCGGG
- TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG AGTTCCTAGA ATGGCGACAA CTCTAGGTCA AGCTACATTG GGTGAGCACG TGGGTTGACT AGAAGTCGTA GAAAATGAAA GTGGTCGCAA AGACCCACTC 5701
- CAAAAACAGG AAGGCAAAAT GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT CAATATTATT GAAGCATTTA GTTTTGTCC TTCCGTTTTA CGGCGTTTTT TCCCTTATTC CCGCTGTGCC TTTACAACTT ATGAGTATGA GAAGGAAAAA GTTATAATAA CTTCGTAAAT 5801
- CGGTGGACTG GCCACCTGAC 5901 TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT AGICCCAAIA ACAGAGIACI CGCCIAIGIA IAAACIIACA IAAAICIIII IAITIGIIIA ICCCCAAGGC GCGIGIAAAG GGGCIIIIICA
 - 6001 GICTAAGAAA CCAITAITAI CAIGACAITA ACCIAIAAAA AIAGGCGIAI CACGAGGCCC ITICGICIIC AA (SEG 10 NO: 99) CAGAIICIII GGIAAIAAIA GIACIGIAAI IGGAIAIIII IAICCGCAIA GIGCICCGGG AAAGCAGAAG II

177	(ah) = 12	10 20 30 DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ
	B1.6	DIQTTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ
		DIOTIQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ
	0101	DIOTTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ
	0101	DIOTTQSPSSLSASVGDRVTITORANEOLSNYLNWYQQ
1	0172	CDR-L1
म	(ab)-12	40 50 60 CDR-DI 70 KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS
	B1.6	KPGKAPKILIYFTSSLHSGVPSRFSGSGSGTDXTLTIS
	2305.6	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDXTLTIS Fig. 9A
	0101	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS
	0192	KPGKAPKVLIY <u>FTSSLHS</u> GVPSRFSGSGSGTDFTLTIS
F	'(ab)-12	CDR-L2 80 SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV(5EQ 10 No:8)
	B1.6	SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (SEQ 1D NO: 101)
Н	2305.6	SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (5EQ 10 No:103)
Y	0101	SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (SEQ 10 NO:105)
Y	0192	SLQPEDFATYYCOOYSTVPWTFGQGTKVEIKRTV (SEQ 10 No: 107)
		CDR-L3
		10 20 30
		EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVR
	IB1.6	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWIR
_	12305.6	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWIR
	70101	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVR
Υ	70192	EVQLVESGGGLVQPGGSLRLSCAAS <u>GYTFTNYGEN</u> WVR
	7/ah	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA
	r(ab)-12 MB1.6	QAPGKGLEWVGWINTYTGEPTYAADFKRRFT SADTS NIV
_	181.6 12305.6	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSADTSSNIV Fig. 9B
	70101	OAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA
	70192	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA
_	10172	CDR-H2 CDR-7
F	7(ab)-12	80 90 CDR-H2 100 110 CDR-7 PYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL(JEQ ID NO:7)
	4B1.6	YLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL(SEQ 1D NO: 102)
	12305.6	YLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL(SEQ ID NO: 104)
	0101	YLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL (SEO IDNO: ID6)
	70192	YLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL (SEQ ID NO:108)
•		CDR-H3

≡ difference	es from F(ab)-12			
	10 20 30			
•	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ			
Y0243-1				
Y0238-3	DIQTIQSPSSLSASVGDRVTITCRANEOUSNYLNWYQQ			
Y0313-1	DIQTTQSPSSLSASVGDRVTITCRANEOTSNYLNWYQQ			
Y0317	Y0317 DIQTTQSPSSLSASVGDRVTITC <u>SASODISNYLN</u> WYQQ			
	CDR-L1 70			
F(ab)-12	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS			
Y0243-1	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS			
Y0238-3	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS Fig. 10A			
Y0313-1	KPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTIS			
Y0317	KPGKAPKVLIY <u>FTSSLHS</u> GVPSRFSGSGSGTDFTLTIS			
	80 CDR-L2 90 100			
F(ab)-12	SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVCSEQ 10 NO:8)			
Y0243-1	SLOPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV(5EQ 1D NO: 104)			
Y0238-3	SLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (SEQ ID NO: III)			
Y0313-1	SLOPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (SEQ ID NO. 115)			
Y0317	SLQPEDFATYYC <u>OOYSTVPWT</u> FGQGTKVEIKRTV(SEQID NO: 115)			
	CDR-L3			
	10 20 30			
F(ab)-12	10 20 30 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVR			
Y0243-1	EVQLVESGGGLVQPGGSLRLSCAASGYDF"IMYGMNWVR			
Y0238-3	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGINWVR			
Y0313-1	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVR			
Y0317	EVQLVESGGGLVQPGGSLRLSCAAS <u>GYDFTHYGMN</u> WVR			
	40 50 60 CDR-H1 70			
	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA			
Y0243-1	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA			
Y0238-3				
Y0313-1	QAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA			
Y0317	QAPGKGLEWVG <u>WINTYTGEPTYAADFKR</u> RFT <u>FSLDTSKSTA</u>			
	80 90 CDR-H2 100 110 CDR-7			
F(ab)-12	YLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTL(SEQ IDNO:7)			
Y0243-1				
Y0238-3	YLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTL (SEQ ID NO: 112)			
Y0313-1	YLQMNSLRAEDTAVYYCAKYPWYYGTSHWYFDVWGQGTL (SEQ ID NO: 114)			
Y0317	YLQMNSLRAEDTAVYYCAK <u>YPWYYGTSHWYFDV</u> WGQGTL (SEQ ID NO. 110)			
	CDR-H3			

CDR-H3





Fig. 11



Express Mail No.: EL599584388US Atty. Docket No.: P1093P1D1 Date Mailed: November 27, 2000

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY FOR CONTINUING APPLICATION

As a below named inventor, I hereby declare that:

Ginger R. Dreger - Reg. No. 33,055

Sean A. Johnston - Reg. No. 35,910

Jeffrey S. Kubinec - Reg. No. 36,575

Janet E. Hasak - Reg. No. 28,616

Dennis G. Kleid - Reg. No. 32,037

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ANTI-VEGF ANTIBODIES

the specification of which (check one) _ is attached hereto or X was filed on 06 August 1997 as Application Serial No. 08/908.469 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed: Prior Foreign Application(s): Priority Claimed Yes _No_ Number Country Day/Month/Year Filed hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below: Application Ser. No. Filing Date hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application: 08/833,504 April 7, 1997 Pending Application Ser. No. Filing Date Status: Patented, Pending, Abandoned Application Ser. No. Filing Date Status: Patented, Pending, Abandoned POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Walter E. Buting - Reg. No. 23,092 Wendy M. Lee - Reg. No. 40,378 Deirdre L. Conley - Reg. No. 36,487

Richard B. Love - Reg. No. 34,659

Diane L. Marschang - Reg. No. 35,600

Timothy R. Schwartz - Reg. No. 32,171

Craig G. Svoboda - Reg. No. 39,044

Daryl B. Winter - Reg. No. 32,637

Timothy E. Torchia - Reg. No. 36,700

Send correspondence to Genentech, Inc.

Attn: Wendy M. Lee

1 DNA Way

South San Francisco, CA 94080 Telephone: (650) 225-1994

I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor	
Manuel Baca	
Inventor's signature	Date
Manuel Lace.	11/28/97
Residence	
888 Foster City Boulevard, Foster City, California 94404	
Citizenship	
_Australia	
Post Office Address	
1 DNA Way	
South San Francisco, CA 94080	
Full name of second joint inventor, if any	
James A. Wells	
Inventor's signature	Date .
James An Welle	10/29/07
Residence	10/0/1/7
341 Columbus Avenue, Burlingame, California 94010	
Q jizenship	
Vnited States of America	
Post Office Address	
1 DNA Way	
South San Francisco, CA 94080	
Full name of third joint inventor, if any	
Leonard G. Presta	14 31 67
	10-31-97
Inventor's signature	Date
Deonard D. Presta	
Residence	
1900 Gough Street #206, San Francisco, California 94109	
Citizenship	
United States of America	
Post Office Address	
1 DNA Way	
South San Francisco, CA 94080	

All annual formation of the second se	
ull name of fourth joint inventor, if any	
Henry B. Lowman	
Inventor's signature Lung Be Journe	10/29/97
Residence 400 San Juan Avenue, El Granda, California 94018	
itizenship United States of America	
Post Office Address 1 DNA Way South San Francisco, CA 94080	
full name of fifth joint inventor, if any	
Yvonne Man-yee Chen	
Inventor's signature Notable Chien	Date / 6/39/97
Residence	
1951 O'Farrell Street #321, San Mateo, California 94403	
Citizenship Canada	
Post Office Address 1 DNA Way South San Francisco, CA 94080	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Manuel Baca et al.

Serial No.: To Be Assigned

Filed: Herewith

For:

ANTI-VEGF ANTIBODIES

Group Art Unit:

Examiner:

CERTIFICATE OF MAILING

hereby certify that thisicographopondence is being deposited with the United States Aostal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Parents, Washington, D.C. 2029 of

November 27, 2000

Eileen Ly

ASSOCIATE POWER OF ATTORNEY (37 CFR 1.34)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Please recognize as Associate Attorney in this case:

Steven X. Cui - Reg. No. 44,637

Please direct all communications relative to said pending patent application to the following address:

Steven X. Cui Genentech, Inc. 1 DNA Way

South San Francisco, CA 94080-4990 Telephone: (650) 225-8674

Respectfully submitted, GENENTECH, INC.

Date: November 27, 2000

By: Cant E. Hasak

Yanet E. Hasak Reg. No. 28,616

Telephone No. 650-225-8674

09157

PATENT TRADEMARK OFFICE